Functional analysis across model systems implicates ribosomal proteins in

growth and proliferation defects associated with hypoplastic left heart syndrome

Tanja Nielsen[1,6,*], Anaïs Kervadec[1,*], Jeanne L. Theis[2,*], Maria A. Missinato[1], James

Marchant[1], Michaela Romero[1], Katya Marchetti[1], Aashna Lamba[1], Xin-Xin I. Zeng[1], Marie

Berenguer[1], Stanley M. Walls[1], Analyne Schroeder[1], Katja Birker[1], Greg Duester[1], Paul

Grossfeld[5], Timothy J. Nelson[3], Timothy M. Olson[4,], Karen Ocorr[1], Rolf Bodmer[1,#], Georg

Vogler[1,#], Alexandre R. Colas[1,#]

[1] Center for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical

Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA

[2] Cardiovascular Genetics Research Laboratory, Mayo Clinic, Rochester, MN, USA

[3] Center for Regenerative Medicine, Division of Pediatric Cardiology, Department of

Pediatric and Adolescent Medicine, Division of General Internal Medicine, Department of

Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester,

MN, USA

[4] Department of Cardiovascular Medicine, Division of Pediatric Cardiology, Department

of Pediatric & Adolescent Medicine, Cardiovascular Genetics Research Laboratory, Mayo

Clinic, Rochester, MN, USA

[5] University of California San Diego, Rady Children's Hospital, San Diego, CA, USA.

[6] Department of Biochemistry, Chemistry and Pharmacy, Freie Universität Berlin, Berlin,

Germany

23
24
25 * These authors contributed equally

26
27 # Co-corresponding authors

29   Keywords: Congenital heart disease, HLHS, whole genome sequencing, rare variant

30   filtering, cardiogenesis, *Drosophila*, iPSC, zebrafish, *RPS15A*, *TP53*, *yorkie*,

31   *tinman/NKX2-5, Dorsocross/TBX5, pannier/GATA6*.

Abstract

Hypoplastic left heart syndrome (HLHS) is the most lethal congenital heart disease (CHD). The pathogenesis of HLHS is poorly understood, and due to the likely oligogenic complexity of the disease, definitive HLHS-causing genes have not yet been identified. Postulating impaired cardiomyocyte proliferation as a likely important contributing mechanism to HLHS pathogenesis, and we conducted a genome-wide siRNA screen to identify genes affecting proliferation of human iPSC-derived cardiomyocytes (hPSC-CMs). This yielded ribosomal protein (RP) genes as the most prominent class of effectors of CM proliferation. In parallel, whole genome sequencing and rare variant filtering of a cohort of 25 HLHS proband-parent trios with poor clinical outcome revealed enrichment of rare variants of RP genes. In addition, in a familial CHD case we identified a rare, predicted-damaging promoter variant affecting *RPS15A* that was shared between the HLHS proband and a distant relative with CHD. Functional testing with an integrated multi-model system approach reinforced the idea that RP genes are major regulators of cardiac growth and proliferation, thus potentially contributing to the hypoplastic phenotype observed in HLHS patients. Cardiac knockdown (KD) of RP genes with promoter or coding variants (*RPS15A, RPS17, RPL26L1, RPL39, RPS15*) reduced proliferation in generic hPSC-CMs and caused malformed hearts, heart-loss or even lethality in *Drosophila*. In zebrafish, diminished *rps15a* function caused reduced CM numbers, heart looping defects, or weakened contractility, while reduced *rps17* or *rpl39* function caused reduced ventricular size or systolic atrial dysfunction of the atrium, respectively. Importantly, genetic interactions between *RPS15A* and core cardiac transcription factors *TBX5* in CMs, *Drosocross, pannier* and *tinman* in flies, and *tbx5* and *nkx2-7* (*nkx2-5* paralog) in fish, support a specific role for RP genes in heart development. Furthermore, *RPS15A* KD-induced heart/CM proliferation defects were significantly attenuated by *p53* KD in both hPSC-CMs and zebrafish, and by Hippo activation (*YAP/yorkie* overexpression) in developing fly hearts. Based on these findings, we conclude that RP genes play novel critical roles in cardiogenesis and constitute an emerging class of gene candidates likely involved in HLHS.

Introduction

Hypoplastic left heart syndrome (HLHS) accounts for 2-3% of all cases of congenital heart disease (CHD) [1, 2] and is characterized by underdevelopment of the left ventricle, mitral and aortic valves, and aortic arch [3]. HLHS has a recognized genetic component based on its familial association with left-sided obstructive congenital heart diseases [4-6]. However, segregation analyses in multiplex HLHS-CHD families [6] and genome-wide association studies (GWAS) of large cohorts [5] have lacked sufficient power to conclusively identify candidate HLHS-susceptibility genes with small to moderate effect sizes. Defects in a small number of genes involved in cardiogenesis, such as *NOTCH1* [7], *NKX2–5* [8], *MYH6* [9], and *GATA4* [8, 10] have been implicated as contributors to HLHS, as well as multiple other CHDs. However, the variety of phenotypic manifestations of HLHS, together with numerous studies linking it to diverse genetic loci [7-9, 11], suggests that HLHS is genetically heterogeneous and has a multigenic etiology [12, 13].

It has also been hypothesized that the underdevelopment of the left ventricular myocardium includes restricted blood flow across the mitral valve and its hemodynamic effect during ventricular growth and development ("no flow – no grow" [14]), as well as endocardial defects [15]. Therefore, HLHS manifestation may be due to a combination of cardiomyocyte autonomous and non-autonomous genetic as well as mechanical effects, all of which likely affect proliferation and differentiation in the developing heart.

In a digenic HLHS mouse model, loss of both Sin3A Associated Protein 130 (*Sap130)* and the protocadherin *Pcdha9* cause decreased CM proliferation resulting in left ventricular (LV) hypoplasia [16]. In addition, LVs from HLHS patients have cardiac damage associated with CM proliferation defects compared to healthy subjects [17]. These studies suggest that intrinsically defective cardiac differentiation and impaired CM proliferation are likely contributing to HLHS-associated heart defects. Further strengthening this hypothesis, we found that HLHS-patient-derived hPSC-CMs exhibited reduced proliferation compared to the parents [18]. There is a need to identify the potentially causative genes, which contribute to those processes described above and to elucidate their role HLHS pathogenesis.

To advance CHD gene discovery, we have developed a multi-model systems
platform enabling to both rigorously prioritize candidate genes from whole-genome
sequencing (WGS) based on rare, predicted-damaging variants and their mode of
inheritance, and to functionally characterize gene function in complementary and
genetically tractable model systems: human induced pluripotent stem cells (hPSC), the
fruit fly *Drosophila melanogaster* and zebrafish *Danio rerio*. The genetic basis of cardiac
development, originally uncovered in *Drosophila*, is fundamentally conserved across
species [19-22] and ~80% of human disease genes have fly orthologs [23]. In addition,
the non-redundant fly genome together with the simple structure and function of the fly
heart allow straightforward genotype-phenotype correlations. Zebrafish [24-26], which
has a two-chambered heart and can be easily manipulated using morpholino injections
and CRISPR technologies to affect heart development and function. In addition,
phenotypes can be directly observed in the developing larva for several days post
fertilization [27]. Finally, cardiomyocytes (CMs) differentiated from hPSCs (hPSC-CMs)
enable to identify and quantify cellular phenotypes associated with human diseases,
including HLHS [7, 28-30] and are amenable to large scale functional screens [31, 32],
thereby enabling to serve both as a discovery and validation platform. This integrated
approach allows to rapidly identify novel HLHS-associated gene candidates and to
characterize their ability to regulate developmental processes associated with disease
(e.g., hypoplasia) [18].

Defective CM proliferation is likely a hallmark of HLHS [16-18], thus to uncover
novel regulators of human CM proliferation with potential links to HLHS, we performed a
whole genome siRNA screen (18,055 genes) using an EdU assay in hPSC-CMs and
identified ribosomal proteins (RPs) as the major class of genes controlling CM
proliferation. In parallel, whole genome sequencing (WGS) of 25 poor-outcome HLHS
proband-parent trios followed by unbiased variant filtering, revealed an enrichment for
rare, predicted-damaging variants in RP genes. Moreover, analysis of a high-value family
(75H) comprised of a HLHS proband, his phenotypically normal parents, and a fifth
degree relative born with left-sided CHD led to the identification of a predicted-damaging
variant in RP protein gene *RPS15A* that segregated with disease. Consistent with a
central role for RPs in the regulation of heart development, heart-specific knock-down

(KD) of HLHS-associated RPs in *Drosophila* caused severe phenotypes, including near
complete heart-loss and lethality. Similarly, in zebrafish, *rps15a* CRISPR mutants and
morphants had greatly reduced heart size and CM number, looping defects and
diminished contractility. In this context, a multi-model system evaluation (hPSC-CMs, flies
and zebrafish) of RP function show their important role on heart growth and differentiation
and CM proliferation by modulating the p53, Myc and Hippo pathways. Moreover, we find
evidence that RPs may regulate heart development and CM proliferation in a cardiac-
specific manner by synergistically interacting with core cardiac transcription factors such
as T-box, Nkx and Gata factors. In sum, here we show that RP genes are potent
regulators of CM proliferation and cardiac growth and differentiation, consistent with a
potentially critical role in the hypoplastic phenotype of HLHS. We suggest that RP genes
are an emerging class of novel genetic effectors in HLHS.

Results

Whole genome siRNA screen identifies ribosomal proteins as central regulators of cardiomyocyte proliferation

Based on previous and our recent data [16-18], impaired CM proliferation is emerging as an important mechanism in HLHS pathogenesis. Thus, to comprehensively map the human genome for novel regulators of CM proliferation, we screened a library of 18,055 siRNAs for their ability to modulate proliferation in human iPSC-derived CMs (hPSC-CMs). To assess CM proliferation, we used a dual read-out and quantified both DNA synthesis using EdU incorporation [31], and total number of CMs, 3 days after treatment (**Figure 1A-C**). Briefly, siRNAs were transfected into 25-day old hPSC-CMs [29, 33]. After 2 days, EdU was added to the wells for 24 hours. On day 3, cells were fixed and co-stained for sarcomeric protein alpha-Actinin (ACTN2), EdU, and DAPI. Next, the number of EdU/alpha-Actinin double-positive cells, and the total number of CMs were determined using a commercially available high-throughput image analysis software (MetaXpress, Molecular Devices)[31]. Note that alpha-Actinin-, EdU+ cells which typically express fibroblast markers (i.e POSTN)[34], were excluded from this analysis, to focus on CM biology only. In total, we found 153 siRNAs that decreased proliferation (< 0.5-fold EdU incorporation) and number of CMs (<0.8-fold), and 162 siRNAs that increased EdU (>1.2-fold) and CM number (>1.1-fold; **Figure 1B, C and Supplemental Table 1 WGS data**). Consistent with previous studies [35, 36], KD of cell cycle checkpoint agonist, CHEK1 and MDM2, the negative regulator of TP53, both were among top hits that reduced CM proliferation. As expected, we identified TP53 and CDKN1A among the genes that significantly increased CM cell number upon KD (**Figure 1B, C**). Next, to gain insight into the molecular pathways regulating proliferation in hPSC-CMs, we performed Gene Ontology (GO) term analysis of hits decreasing EdU incorporation or CM numbers and found an enrichment for genes associated with "translation/ribosome" and p53 signaling as top hits (**Figure 1D, E**). Consistent with these observations, we had previously found that the p53 pathway is dysregulated in hPSCs differentiated from a HLHS family trio [18]. Remarkably, the most represented gene family are ribosomal proteins (RPs), KD of which caused consistently the strongest inhibition of cell

proliferation (**Figure 1B**). Next, since, the primary screen was performed as a single data
point, we next sought to validate these findings by re-testing all 80 RP genes for function
[37] using a distinct set of siRNAs in biological quadruplicate conditions. Remarkably and
consistent with the primary screen, KD of 59/80 RPs significantly reduced proliferation as
compared to siControl (p<0.05; **Supplemental Figure 1A, B**). In this context, further
functional testing in fibroblasts revealed that the antiproliferative effect of RP loss of
function is cell type–independent (**Supplemental Figure 1C, D**). Together, these findings
establish RP function as essential for cell proliferation, including in hPSC-CMs, and
suggest that RPs may represent a previously unrecognized class of regulators of
ventricular growth during embryonic development.
178

Enrichment of RP gene variants in an HLHS patient cohort with poor clinical
outcome

To identify candidate genes involved in HLHS pathogenesis, we performed whole
genome sequencing (WGS), variant filtering, and enrichment analysis (see also [18], and
Methods: WGS and bioinformatic strategies) in a cohort of 25 HLHS patient-parent trios
with poor clinical outcome defined as either prenatal – restrictive atrial septal defect (n=2);
postnatal – reduced right ventricular ejection fraction following stage II or III surgical
palliation (n=19); protein-losing enteropathy (n=2); or cardiac transplantation/failed
surgical palliation (n=2). The 25 probands were comprised of 18 males and 7 females, 24
of whom were of white ancestry. The HLHS phenotype with respect to valve morphology
(mitral atresia, MA; mitral stenosis, MS; aortic atresia, AA; aortic stenosis, AS) was:
MA/AA in 10, MS/AS in 9, MA/AA in 4, MA/AS in 1 and unknown in 1. CHD in the parents
was excluded by echocardiography in all but two families, in which a bicuspid aortic valve
was present in the mother. Genomic sequences were filtered for uncommon (MAF < 1%)
de novo and recessive variants in coding and regulatory regions of genes expressed in
the developing heart and predicted to alter protein structure or expression, yielding 292
unique HLHS candidate genes that primarily fit a recessive mode of inheritance (Figure
2A and Supplemental Table 2). To determine whether certain gene networks were over-
represented among these variants, we used two online bioinformatics tools (STRING and
PANTHER [38, 39]). After applying Fisher's exact test and false discovery rate

corrections, RPs were the most enriched class of proteins when compared to the
reference proteome, which includes data annotated by protein class (5.24-fold,
p=0.0028), and cellular component (7.27-fold, p=0.011). In total, 14 variants found in 9
RP genes among 6 HLHS probands were identified, most fitting a recessive inheritance
disease model (**Table 1**). These RP variants encompass mutations in upstream promoter
regions that potentially affect transcription factor binding sites, as well as non-
synonymous substitutions inside the protein coding regions.

Next, all 292 prioritized candidate genes were systematically evaluated for effects
on the proliferation of hPSC-CMs *in vitro* and for cardiac differentiation of fly hearts *in*
vivo. Again, loss of RP function (*RPL39, RPL26L1, RPS15, RPS17, RSPS28*) caused the
most severe phenotypes on proliferation in hPSC-CMs (**Figure 2B, Supplemental Table**
3), which was consistent with our genome-wide proliferation screen (see **Figure 1B**). In
the fly, KD of RPs in the cardiac lineage and throughout embryonic development was
achieved using a *Hand$^{4.2}$*-Gal4 driver (see [40] and methods) and led to partial or
complete heart loss (*RpL26, RpL36A, RpL3*) or caused lethality (*RpS17, RpL39, RpS15,*
RpL26, RpL36A) (Figure **2C**). Also, KD of *RpL10* gave rise to severely constricted hearts,
while KD of *RpS28b* caused inflow tract defects (**Figure 2C**). Finally, functional testing of
RPs in zebrafish embryos revealed that KD of *rpl39* leads to reduced ventricle size,
whereas *rps17* CRISPR mutants exhibit systolic dysfunction (**Figure 2D, E**). In sum, our
patient centric approach (cohort of 25 probands) identifies RPs as the most enriched gene
category affected by HLHS-associated variants (STRING, PANTHER analysis). In this
context, systematic testing in multi-model systems (fly, zebrafish, hPSC-CMs) identifies
RPs as most potent regulators of cardiac differentiation, proliferation and contractility
among HLHS-associated genes. Collectively, these findings highlight that RPs regulate
critical steps of cardiogenesis that are also found to be defective in HLHS probands [41,
42] and thus suggest a potential link between RP biology and HLHS phenotypic etiology.
225

RPS15A variant associated with HLHS in familial CHD

To further establish a phenotypic link between RP function and HLHs associated
phenotypes, we selected a rare familial CHD case (75H) (**Supplemental Figure 2A**), that

is comprised of a young teenager with HLHS (MS/AS) and normal ventricular function
following Fontan operation, his phenotypically normal parents, and a 5th degree female
relative born with left-sided CHD (bicuspid aortic valve and coarctation of the aorta).
Based on these observations, we hypothesized the presence of a heterozygous driver
variant exhibiting incomplete penetrance and variable expression. To investigate further,
we filtered whole-genome sequencing (WGS) data for rare, predicted-damaging variants
in coding and regulatory regions. This analysis identified six prioritized variants
(**Supplemental Table 4**), including one located in the *RPS15A* gene locus, shared by the
HLHS proband, the unaffected mother, and the proband's fifth-degree relative with
congenital heart disease (CHD).
We next investigated whether family members carrying these variants (the mother
and proband) exhibit defects in cardiomyocyte (CM) proliferation compared to the father.
Notably, analysis of EdU incorporation in CMs from the parent-proband trio revealed
significantly reduced proliferation in both the proband and mother compared to the father.
However, the proband displayed a markedly more severe phenotype than the mother
(**Figure 3 A,B**). Interestingly, this reduction in proliferation appeared to be specific to
cardiomyocytes (CMs), as EdU incorporation in the non-CM cell population showed no
significant differences among the family members (**Supplemental Fig. 2B**). Collectively,
these findings suggest a phenotypic association between the presence of the variants
and impaired CM proliferation.
Finally, to determine the potential relative contribution of the six genes harboring
rare and damaging variants in the regulation of CM proliferation, we performed functional
KD experiments in hPSC-CMs *in vitro*. Remarkably, while KD of 5 of the other prioritized
genes from the 75H family also resulted in moderate reduced CM proliferation, RPS15A
KD produced the most pronounced effect, with over an 85% reduction in proliferation,
emerging as the top candidate (**Figure 3C, D**). Together, these findings indicate that
RPS15A plays a critical role in regulating cardiomyocyte (CM) proliferation in human
pluripotent stem cells (hPSCs) and may influence heart developmental processes that
are disrupted in HLHS.
258

RPS15A KD in *Drosophila* and zebrafish causes severe cardiac proliferation and differentiation defects

To characterize the role of *RPS15A* during heart development, we first induced a heart-specific KD of *RpS15Aa* in flies (see methods), which caused a partial or complete loss of the heart (**Figure 3E,F**). Note that this phenotype is consistent with our results above and a previous study involving another RP gene (*RPL13*) [43].

Next, to evaluate the role of *RP* genes during heart development, we knocked-out *rps15a* in zebrafish (*Danio rerio*) using CRISPR [24-26]. We examined F_0 larva at 72 hpf (hours post fertilization) using high speed digital imaging (SOHA [44], see also methods) and confocal microscopy to monitor heart size and cardiomyocyte numbers respectively. Remarkably, *rps15a* mutant hearts were smaller in size (**Supplemental Fig. 2C,D**), with reduced CM numbers (**Figure 3G,H**). We observed similar effects in response to injection of a *rps15a* morpholino (MO) compared to uninjected larva [45, 46] (**Supplemental Figure 3 C,D**). In this context, we also noted that the overall body plan and morphology of *rps15a* CRISPR mutants or morphants were largely unaffected, except for a mild pericardial edema, a possible indicator of heart dysfunction (**Figure 3H**) [47].

We quantified cardiomyocyte (CM) number using nuclear markers in Tg(*myl7:eGFP*); Tg(*myl7:H2A-mCherry*) embryos 72 hpf. CM numbers were predominantly reduced in the ventricle compared to the atrium (**Figure 3G,H**). We also assessed total cardiac cell numbers and cardiac cell proliferation by phospho-histone H3 (PH3) immunostaining and DAPI to quantify total cardiac cells. We again found that the total cell numbers were significantly reduced in both rps15a morphants and crispants (**Supplemental Figure 4A-C**). Importantly, the proportion of proliferating (PH3+) cardiac cells was also decreased in rps15a morphants and crispants at both 24 and 48 hpf, but not at 72 hpf when proliferation normally declines (**Supplemental Fig. 4C**). Collectively, these data support the hypothesis that *RPS15A* is required for CM proliferation and heart morphogenesis (hPSC-CMs, fly and zebrafish), thus suggesting a potential role for RPs as genetic drivers of hypoplasticity observed in HLHS.

Ribosomal proteins control CM cell cycle by regulating TP53 pathway activity

To investigate how RPs regulate cell cycle activity in hPSC-CMs, we performed

RNA-seq upon KD of *RPS15A* and *RPL39*, which belong to the small and the large

ribosomal subunits that harbor predicted-damaging variants in 75H and 151H probands,

respectively. Comparison of differential gene expression between *siRPS15A* and

siRPL39 KD revealed that ~53% of genes were commonly dysregulated (**Figure 4A**),

indicating the existence of a conserved RP-dependent transcriptional network. Consistent

with a central role for RPs in the regulation of proliferation, GO term analysis for

differentially expressed genes revealed an enrichment for genes involved in DNA

replication, mitosis and DNA damage response mediated by p53, and included the

downregulation of positive regulators of cell cycle such as *CDK1, CCNA2, AURKA, PCNA*

and the upregulation of cell cycle arrest mediators such as *CDKN1A, BTG2, GADD45A*

(**Figure 4B** and **Supplemental Tables 5,6**). To confirm these findings, we performed

immunostaining for canonical p53 downstream transcriptional target [48], *CDKN1A,* and

observed that the percentage of CDKN1A+ CMs was increased by ~60% in response to

RPS15A KD (**Figure 4C, D**), indicating that RP KD induces cell cycle arrest *via* the

activation of the p53 signaling pathway in hPSC-CMs.

Next, to evaluate if the reduction in proliferation caused by RP KD is mediated by

the p53 signaling pathway in CMs, we co-KD *TP53* or *CDKN1A* along with *RPS15A*, and

observed a significant rescue of CM proliferation by EdU incorporation and CM number

in comparison to RPS15A KD (**Figure 4E, F** and **Supplemental Figure 4D, E**).

Next, we tested if RP-mediated defects in zebrafish can also be rescued by

inhibition of p53. To this aim, we used morpholinos to co-KD *p53* with *rps15a* [49] and

examined larval hearts at 72 hpf. *p53* MO-mediated KD on its own had little effect on

heart function but partially reversed the *rps15a* MO-mediated reduction in heart size and

cardiomyocyte numbers (**Figure 4G, H**). Moreover, bradycardia, heart looping and

reduced contractility phenotypes of *rps15a* morphants were also rescued by co-KD of *p53*

(**Supplemental Figure 4F, G**). Collectively, these observations support our hypothesis

that RPs control cardiac development, including heart size and function, *via* a p53

pathway-mediated regulation of CM proliferation.

Heart loss in *Drosophila* by RpS15Aa KD is partially rescued by Hippo pathway activation

The fly heart develops similarly to the vertebrate heart at early stages [20] and a link between RPs and cell cycle-regulating pathways, such as p53 and Hippo pathways [50], has been proposed to be conserved between mammals and flies [51]. To test whether p53 has a function in fly heart development similar to hPSC-CMs and zebrafish, we performed cardiac co-KD of *RpS15Aa* and *p53* and examined heart structure and function. Co-KD did not rescue the cardiac defects of *RpS15Aa* KD suggesting that *p53* has a different role in flies, as compared to vertebrates, as has been reported previously [52].

In vertebrates, TP53 is known to act through the negative regulation of the Hippo pathway [53]. In this context, YAP, a downstream effector of Hippo, has been shown to promote CM proliferation in the mouse heart [54]. We therefore tested if YAP/yorkie can substitute the function of p53 in the fly heart and found that overexpressing the Hippo pathway gene *yorkie* (*yki*), the fly ortholog of YAP, in the developing heart considerably restored *RpS15Aa* KD-induced heart loss in *Drosophila* (**Figure 5A',B**). We also observe formation of adult ostial structures, which indicates that the larval heart underwent partial remodeling to an adult heart during metamorphosis. Further, we found that *yki*-mediated rescue depends on the transcriptional co-factor encoded by *scalloped* (*sd*, *Drosophila TEAD1/2/3/4*), since upon *sd* KD, *yki* OE can no longer rescue the *RpS15Aa* KD-induced heart loss (**Figure 5A", B**). Moreover, KD of *sd* in an *RpS15Aa* KD background (without *yki* OE) worsens the *RpS15Aa* KD phenotype (**Figure 5A", B**).

RPS15A genetically interacts with cardiac transcription factors *nkx2.7*/*tinman,* and TBX5/*tbx5a*/*Dorsocross*, *nkx2.7*/*tinman,* and *Gata4,5,6*/*pannier* in model systems

The profound importance of RPs for cell growth and proliferation in most cell types ([55] and **Supplemental Figure 1**), raises the question of how tissue specific phenotypes such as those observed in HLHS can arise from the defective function of ubiquitously expressed genes. To address this apparent paradox, we hypothesized that RPs might functionally interact with tissue-specific proteins such as cardiac transcription factors

(cTFs), to control CM proliferation. Analysis of the impact of cTFs alone on hPSC-CM

proliferation from our whole genome screen, revealed that KD of most cTFs did not cause

major proliferation defects (except for e.g., *HES4* and *HOPX*; **Figure 6A**). Among the

cTFs, TBX5 is specifically expressed in the left ventricle at stages of intense CM

proliferation [56] and thus we next asked if *TBX5* could functionally interact with RPs.

Remarkably, while hPSC-CM proliferation was not affected by increasing doses of siTBX5

(0-2nM), increasing si*TBX5* dosage in siRP backgrounds led to proportional decrease in

EdU incorporation (Two-way ANOVA; **Figure 6B and Supplemental Figure 5A,B**),

thereby indicating that *RPs* and *TBX5* genetically interact to regulate proliferation in

hPSC-CMs.

Conservation of genetic interactions between human and fly cardiac transcription

factors and constitutive genes have been identified before [57]. We therefore specifically

tested for genetic interaction between *RpS15Aa* and the cardiac TFs *tinman/NKX2-5,*

pannier/GATA4/5/6 and *Dorsocross/TBX5* in adult *Drosophila* hearts*.* A heterozygous

deficiency covering *RpS15Aa* causes moderate dilation of hearts compared to controls

(**Supplemental Figure 5C)**. However, when *RpS15Aa* was placed *in trans* to loss of

function alleles of cardiac TFs *tinman, pannier* or *Dorsocross1/2/3*, these hearts exhibited

significantly deformed hearts, which is only rarely observed in the single heterozygotes

(Figure **5C, D**). In addition, *RpS15Aa* heterozygous flies showed a prolonged heart period

when combined with a *tinman* or *pannier* heterozygous mutations (**Supplemental Figure**

5C).

Next, we tested whether similar genetic interactions are conserved in zebrafish.

Zebrafish expresses the NKX2-5 ortholog *nkx2.7* in the heart and functional studies have

shown that both *nkx2.5* and *nkx2.7* play critical roles in cardiac development [58]. To

determine whether *rps15a* and *nkx2.7 or tbx5a* genetically interact in zebrafish, we

injected low doses of *rps15a* [45] MO, in combination with *nkx2.7* [59] or *tbx5a* MO.

nkx2.7 MO alone had little effect on heart size, cross-sectional area, or contractility,

whereas double morphants exhibited cardiac dysfunction, with contraction virtually

abolished in some animals (**Supplemental Figure 5D**). Furthermore, we observed a

significant prolongation of the heart period in double morphants (*rps15a* + *nkx2.7* or

rps15a + *tbx5a*) in comparison to each MO alone (Two-way ANOVA; **Supplemental**

Figure 5D, E) consistent with the effects observed in *Drosophila*. Together, these results

highlight the existence of evolutionarily conserved (fly, zebrafish and hPSC-CMs) genetic

interactions between RPs and cardiac TFs genes in the regulation of cardiogenesis.

These data also illustrate how the activity of ubiquitously expressed genes such as RPs,

can be modulated by cell type-specific genes, like cardiac TFs, to achieve tissue-specific

outcomes.

RP-regulated HLHS-associated genes control proliferation in a CM-specific manner

Previous studies and this work show that reduced RP function can lead to tissue-

specific developmental defects, that in turn can be rescued by loss of p53 [60, 61]. While

these findings highlight a downstream role for p53 in the development of RP-dependent

phenotypes, they also imply that RPs can regulate cell cycle and/or p53 activity in a

tissue-specific manner. Thus, to delineate how RPs might control proliferation in a CM-

specific manner, we compared differential gene expression profiles upon the two RP KDs

in hPSC-CMs and undifferentiated hPSCs (**Figure 7A**). Consistent with our hypothesis,

this analysis revealed that RPs regulate the expression of 493 genes in a CM-specific

manner (**Supplemental Tables 5-8**), thereby suggesting the existence of a cell type-

specific (cardiac) transcriptional response to RP loss of function.

Next, to evaluate whether HLHS-associated genes were part of this lineage-

specific transcriptional response, we selected those differentially expressed genes

harboring rare and predicted damaging variants in probands from the poor outcome

cohort and 75H family (**Supplemental Tables 2, 4**). Remarkably, this prioritization

strategy identified 12 genes potentially associated with HLHS (**Supplemental Table 9**),

6 of which were found to also regulate cell cycle activity in hPSC-CMs (**Figure 7B, C**).

Thus, collectively this approach led us to identify an RP-dependent and cardiac-specific

HLHS-associated gene network that supports CM proliferation *via* the upregulation of

EWSR1, MDC1, PKMYT1 and *KIF1C,* and downregulation of *FAT4* and *EPHA4* (**Figure

7D, E**).

To further explore if RP-regulated HLHS-associated genes control proliferation in

a cell type-specific manner, we asked if *EWSR1* KD*,* which elicited the strongest

proliferation phenotype in hPSC-CMs, could regulate proliferation in non-cardiac cell
types such hPSCs. In contrast to hPSC-CMs, siEWSR1 did not affect the number of
OCT4+ cells (**Figure 7F, G**), which suggests that EWSR1 is able to regulate proliferation
CM-specifically. EWSR1 is an RNA/DNA binding protein that regulates transcription and
RNA splicing and plays a major role as oncogenic driver when fused to ETS transcription
factors [62]. In a next step, we tested if EWSR1 regulates CM proliferation by modulating
the p53 pathway. Consistent with this hypothesis, immunostaining for p53 downstream
target, CDKN1A, revealed that EWSR1 KD both increased the percentage of CDKN1A-
positive CMs and decreased EdU incorporation as compared to siControl (**Figure 7H-J**).
Consistent with these observations, *RpS15Aa* deficiency fly line placed *in trans* to loss of
function allele for *cabeza* (*caz*), the ortholog of *EWSR1,* caused prolongation of systolic
interval lengths (**Supplemental Figure 5F)** as compared to controls, suggesting a genetic
interaction between these two genes. Collectively, these results support the conclusion
that RPs can modulate proliferation in a cell type-specific manner, by controlling the
expression of downstream effectors (i.e. *EWSR1*), with a cell type-specific ability to
modulate the p53 pathway activity (**Figure 7K and Figure 8**).

Discussion

Implication of ribosomal proteins as genetic modulators in HLHS pathogenesis
429
Recent work, including our own, strongly suggest that defective cardiac
differentiation and impaired CM proliferation contribute to HLHS-associated heart defects
[16-18]. In this study, we find that ribosomal proteins are critical for maintaining CM
proliferation, as well as cardiac structure and function in fish and fly heart models. We
show a potential role for RP function in cardiac development and HLHS pathogenesis as :
(1) RPs are central regulators of cardiomyocyte proliferation, and (2) RP variants are
enriched in a cohort of poor-outcome HLHS patients; (3) a rare predicted-damaging
promoter variant in *RPS15A* was associated with HLHS in familial CHD (75H); (4) KD of
RPs *in vivo* results in cardiac deficiencies in hPSC-CMs, *Drosophila* and zebrafish, and
(5) induces TP53 signaling and blocks proliferation that can be alleviated by inhibition of
TP53 in the vertebrate models. Interestingly, the transcriptomic response of a previously

reported HLHS proband [18] paralleled these findings and raises the possibility of an
underlying ribosomopathy condition in that HLHS family. While universally important for
cellular growth, an increasing number of variants in RP genes have been linked to CHD
in humans indicating tissue-specific differences in the penetrance of RP gene mutations.
Most notably, ~30% of patients with Diamond-Blackfan anemia [63], a ribosomopathy
characterized by hypo-proliferative, proapoptotic erythropoiesis, also have CHD. In
agreement with another study [46] *rps15a* KD in fish caused a noticeable reduction in
circulating red blood cells.

In addition to RPS15A, *RpL13* was recently identified as a potential candidate gene
involved in CHD from a screen for *de novo* copy number variations (CNVs) in 167 patients
with CHD [43]. Furthermore, the Pediatric Cardiac Genomics Consortium (PCGC) exome
dataset of 2871 patients with CHD identified several rare, predicted-damaging *de novo*
variants in RP genes, 2 of which were found in patients with HLHS [64]. Our finding that
RPs genetically interact with core cardiac transcription factors provides a potential
mechanism for the cardiac specificity of RP phenotypes. In this context, we hypothesize
that RP gene variants might play a role as genetic modifiers (or sensitizers) in the
oligogenic pathogenesis of HLHS.

Cardiac-specific and RP-dependent regulation of proliferation in the context of
HLHS

Defective proliferation in left ventricular CMs is a phenotypic hallmark of HLHS [16,
17], thereby implying the existence of HLHS-associated mechanisms that regulate
proliferation in a CM-specific specific-manner. In this study, we identified RPs as novel
candidate genetic regulators of hypoplastic phenotypes observed in HLHS, as 1) rare,
predicted damaging variants affecting RP genes are enriched in HLHS probands as
compared to healthy controls, 2) KD of most RPs impairs proliferation in hiPSC-CMs
(59/80 tested) and heart development in flies (6/6 tested), and 3) systemic loss of *rps15A*
function causes heart-specific hypoplastic phenotypes in zebrafish. However, in this
context, the evaluation of RPs function in multiple cell types revealed that they are
generally required for proliferation (hPSCs, hPSC-CMs and dermal fibroblasts), thus,
indicating that RP loss of function triggers a non-cell type specific cell cycle block.

Thus, an appealing mechanism by which RP function could be invoked in a
spatially restricted manner would involve the regulation of RP expression by cell type-
specific TFs. Consistent with this model, all probands harboring RP variants contain
mutations affecting their promoter regions (**Table 1**). Also, several of these mutations are
predicted to disrupt the binding site of previously identified HLHS-associated TF, ETS1
[15, 65]. Consistent with these observations, a recent study from the Bruneau lab [66]
show that 38 RP genes are downregulated in TBX5-null hiPSC-CMs and ChIP analysis
[67] reveals that a third of these dysregulated RPs (14/38 genes) are bound by TBX5 at
their core promoter regions. Thus, we speculate that cell type specific TFs controlling RP
expression represent a promising gene class enabling to modulate RP-dependent
proliferation in a tissue-specific manner.

A second mechanism by which RPs might control proliferation and differentiation
in a CM-specific manner, is based on the hypothesis that CMs may be molecularly more
sensitive to RP loss-of-function than other cell types. Consistent with this model, RP
deficiency predisposes flies, fish and hPSC-CM for interactions with core cardiogenic
TFs, including TBX5/*Doc*, GATA4/*pnr* and NKX2-5/*tin*, the latter being the most cardiac
restricted. (**Fig.** 6). Moreover, our comparative transcriptomics analysis (**Figure 4**)
revealed that RPs regulate gene expression in a CM-specific manner. Among these RP
regulated genes, *EWSR1, MDC1, PKMYT1, KIF1C, FAT4 and EPHA4*, were found to be
mutated in HLHS families and regulate CM proliferation (**Figure 7**). Remarkably, EWSR1
KD did not affect proliferation in hPSCs, while it strongly reduced EdU incorporation in
hPSC-CMs, thus suggesting that EWSR1 regulates proliferation in a CM-specific manner.
Interestingly, in flies *RpS15Aa* genetically interacts with *cabeza* (*caz,* the fly ortholog of
EWSR1). Consistent with our observations, a recent study has found that overexpression
of a fusion Ewsr1-Fli1 protein in mice specifically induces dilated cardiomyopathy by
promoting apoptosis in cardiac myocytes [68]. Similarly, Fat4, a negative regulator of the
hippo pathway, which is upregulated upon RP KD, was found to specifically regulate heart
size via the regulation of CM size and proliferation [69]. Thus, collectively we propose that
RPs represent a central regulatory hub for cell proliferation and differentiation during
embryonic development, which can be modulated in a cell type-specific manner by tissue-
restricted modulators of RP expression and/or activity.

An RP–MDM2–p53/YAP surveillance network in heart development

Defects in ribosome biogenesis caused, for example, by reduction in RP gene copy
numbers induce a stress response program that activates TP53 (p53) and a cascade of
cellular events resulting in apoptosis, inhibition of the cell cycle or DNA damage response
(reviewed in e.g. [70]), commonly referred to as nucleolar stress response [71] with
activation of TP53 being a key hallmark [72]. A key mechanism involves the release of
RPs to the nucleoplasm, where several RPs bind and inhibit MDM2, which again results
in p53 stabilization and pathway activation [73, 74]. A recent study showed that RP
haploinsufficiency in the developing mouse limb bud also activates a common TP53
cascade but results in TP53-dependent tissue-specific changes of the translatome, which
might confer the specificity often observed in ribosomopathy [60]. The TP53-MDM2
feedback loop is the central molecular node in response to a wide variety of stress signals,
including in the human diseased adult heart [75, 76]. As mentioned above, the
transcriptomic response of the HLHS family 5H [18] also showed activation of the TP53
pathway potentially due to an underlying ribosomopathy. Since low RP levels induce a
proliferation blockade that can be overridden by p53-p21/CDKN1A KD, we hypothesize
that RP levels may act as signaling components sensing cellular fitness and with a
functional outcome either being p53 activation or non-activation. Such an RP–MDM2–
p53 surveillance network was previously proposed to be important in response to nutrient
availability changes and inhibition of oncogenic activity [77, 78]. Thus, the inhibition of the
RP-MDM2-p53 axis might be a therapeutic avenue to consider for functional intervention,
although further studies are needed, to identify the upstream mechanisms leading to the
p53 pathway activation observed in HLHS proband cells.

Heart-specific KD of the *RpS15Aa* in *Drosophila* causes constriction of larval hearts and
atrophy in adult hearts, due to heart loss during metamorphosis, which could not be
rescued by p53 reduction, unlike in hPSC-CMs and zebrafish. This might be due to a
different, context-dependent role of *p53* in flies previously reported to cause a dwarfing,
Minute-like phenotype [79]. We hypothesized that the loss of RPs in flies, in conjunction
with reduced protein synthesis, might cause nucleolar stress, triggering a cell-intrinsic

signaling cascade that prevents the heart to further differentiate and grow. To determine
whether cardiac KD of *RpS15Aa* causes nucleolar stress in the *Drosophila* heart, we
stained larval hearts for Fibrillarin, a marker for nucleoli and nucleolar integrity. We found
that *RpS15Aa* KD causes expansion of nucleolar Fibrillarin staining in cardiomyocyte,
which is a hallmark of nucleolar stress (**Suppl. Fig. 6A-C**). As a control, we also
performed cardiac KD of *Nopp140*, which is known to cause nucleolar stress upon loss-
of-function. We found a similar expansion of Fibrillarin staining in larval cardiomyocyte
nuclei (**Suppl. Fig. 6C,D**). This suggests that *RpS15Aa* KD indeed causes nucleolar
stress in the *Drosophila* heart, that likely contributes to the dramatic heart loss in adults.

The role of the Hippo pathway to regulate cell growth/organ size, proliferation, and
survival, and its importance in cardiac biology is conserved between humans and fly [80-
83]. The Hippo-YAP pathway is a cell-intrinsic pathway that regulates cardiomyocyte
proliferation and thus heart size during development, as demonstrated by the ability of
activated Yap to induce postnatal CM regeneration [84]. Interestingly, we find here that
overexpression the *Drosophila* ortholog of YAP/TAZ, Yorkie, rescues *RpS15Aa* KD-
induced heart loss, dependent on its downstream factor *scalloped* (the *Drosophila*
ortholog of *TEAD1/2/3/4)* (Figure **5**). Of note, YAP1 is not only an important regulator of
cardiomyocyte proliferation in the embryo but also promotes cardiomyocyte survival and
growth in the postnatal heart [85, 86], which is in line with our findings. Interestingly, a
proband among the PCGC HLHS patients was transheterozygous for mutations in *RPL15*
and *TEAD4* [64], making this an interesting disease candidate pair.

Rapid Gene Discovery and Prioritization Approach for Complex Genetic Diseases.

Uncovering the genetic basis of polygenic and heterogeneous diseases, such as HLHS,
remains a significant challenge. This difficulty arises from the lack of experimental
approaches capable of rapidly determining the role and contribution of genetic variants,
as well as their epistatic relationships, in generating disease-associated phenotypes. The
current state-of-the-art approach involves using CRISPR-mediated editing or correction
of gene variants [87], which is effective for analyzing single-family pedigrees. However,
this method is impractical for prioritizing the large number of candidate genes identified

through cohort-wide analyses. Consequently, progress in gene discovery for HLHS has
been limited in recent years [12, 88]. In this study, we aimed to address these limitations
by employing a HT and unbiased exploration of genes regulating a conserved HLHS-
relevant phenotype [41, 89-91], such as reduced CM proliferation, in hiPSCs. Notably,
results integration from a whole-genome functional screen in hiPSC-derived CMs (**Figure
1**, RPs are top hits from the screen), genomic data from a HLHS parent-proband cohort
(**Figure 2**, RPs represent the most enriched gene class containing rare damaging
variants), hiPSC-CM phenotyping from a high value HLHS family (75H), and functional
validation in two independent *in vivo* model systems (**Figure 3**), identified RPs as a novel
class of HLHS-associated genes. While our study highlights the potential of this approach
for gene prioritization, additional research is needed to directly demonstrate the functional
consequence of the identified genetic variants, to verify an association between RP
encoding genes and HLHS in other patient cohorts with and without poor outcome, and
determine if RP variants have a broader role in CHD susceptibility. In conclusion, we
propose that the approach outlined in this study provides a novel framework for rapidly
prioritizing candidate genes and systematically testing them, individually or in
combination, using a CRISPR/Cas9 genome-editing strategy in mouse embryos [33].
Applied in the context of complex genetic diseases, this framework has the potential to
yield deeper insights into their underlying mechanisms.
583
584
585

Acknowledgements

This work was supported by a grant from the Wanek Foundation at Mayo Clinic in
Rochester, M.N., to J.L.T., T.J.N., T.M.O., R.B. and A.R.C. We gratefully acknowledge
the patients and families who participated in this study. We thank Marco Tamayo for
excellent technical assistance. This work was supported by National Institutes of Health
(R01 HL054732 to R.B.; R01 HL153645, R01 HL148827, R01 HL149992, R01 AG071464

to A.R.C.); by California Institute for Regenerative Medicine (DISC2-10110 to A.R.C.); by

the American Heart Association (AHA Predoctoral Fellowship 18PRE33960593 to K.B.).

596 MATERIALS AND METHODS

597 Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Genetic reagent (*D. melanogaster*)	*Hand*^{4.2}-Gal4	NA	PMID: 16467358	NA
Genetic reagent (*D. melanogaster*)	R94C02::tdTomato	Y. N. Jan lab	FBtp0137272	NA
Genetic reagent (*D. melanogaster*)	UAS-RpS15Aa^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0010198	v19198
Genetic reagent (*D. melanogaster*)	Df(RpS15Aa)	Bloomington Drosophila Stock Center (BDSC)	FBab0047266	39614
Genetic reagent (*D. melanogaster*)	UAS-RpL26^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0036825	v40402 v100280
Genetic reagent (*D. melanogaster*)	UAS-RpL36A^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0031980	v108391
Genetic reagent (*D. melanogaster*)	UAS-RpS15^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0034138	v35415 v104439
Genetic reagent (*D. melanogaster*)	UAS-RpL39^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0023170	v23578 v108821
Genetic reagent (*D. melanogaster*)	UAS-RpL3^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0020910	v109820
Genetic reagent (*D. melanogaster*)	UAS-yorkie	D. Pan	NA	NA
Genetic reagent (*D. melanogaster*)	UAS-Myc^{RNAi}	Bloomington Drosophila Stock Center (BDSC)	FBgn0262656	25784
Genetic reagent (*D. melanogaster*)	UAS-sd^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0003345	v101497
Genetic reagent (*D. melanogaster*)	*Df(3L)DocA*	I. Reim	Fbab0037663	NA
Genetic reagent (*D. melanogaster*)	tin^{EC40}	Bloomington Drosophila Stock Center (BDSC)	Fbal0032861	78560

Genetic reagent (*D. melanogaster*)	tin^{346}	Bloomington Drosophila Stock Center (BDSC)	Fbal0035787	92964
Genetic reagent (*D. melanogaster*)	pnr^{VX6}	Bloomington Drosophila Stock Center (BDSC)	Fbal0032468	6334
Genetic reagent (*D. melanogaster*)	Df(pnr)	Bloomington Drosophila Stock Center (BDSC)	Fbab0038315	7982
strain, strain background (*Danio rerio*)	Oregon AB wild-type			A commonly used wildtype strain
strain, strain background (*Danio rerio*)	*Tg(myl7:EGFP)^{twu277}*	Tsai Lab, National Taiwan University	PMID:12950077	A transgenic line of zebrafish labeled with heart-specific EGFP fluorescence.
Strain, strain background (*Danio rerio*)	*Tg(myl7:H2A-mCherry)^{sd12}*	Yelon Lab, University of California, San Diego	PMID:24075907	A transgenic line of zebrafish specifically expressing mCherry in cardiomyocyte nuclei.
Antibody	mouse monoclonal anti-ACTN1	Sigma	A7811	1:800
Antibody	Mouse monoclonal anti-POU5F1 (OCT4)	Sigma	P0082	1:500
Antibody	donkey polyclonal anti-mouse Alexa Fluor 568	Invitrogen	A10037	1:500
Antibody	chicken polyclonal anti-GFP	Aves Labs	GFP-1020	1:300
Antibody	rabbit polyclonal anti-mCherry	Rockland	600-401-P16S	1:200
Antibody	donkey polyclonal anti-chicken AlexaFluor 488	Jackson ImmunoResearch	703-545-155	1:200
Antibody	donkey polyclonal anti-rabbit AlexaFluor 568	Invitrogen	A10042	1:200
other	DAPI (iPSC) 500mg/mL	Sigma	D9542	1:1000
Antibody	mouse anti-Mhc (*Drosophila*)	DSHB	3E8-3D3	1:50
Antibody	anti-mouse-Alexa Fluor 488	Jackson Labs	115-545-003	1:500
other	Alexa Fluor 647 phalloidin	Invitrogen	A22287	1:500
other	DAPI (Zebrafish) 500 mg/mL	Invitrogen	D1306	1:200

Sequence based reagent	RPS15A siRNA	Entrez Gene ID: 6210	Dharmacon	On-Target plus, individual sequence
sequence-based reagent	TP53 siRNA	Entrez Gene ID: 7157	Dharmacon	On-Target plus, Individual Sequence
sequence-based reagent	CDKN1A siRNA	Entrez Gene ID: 1026	Dharmacon	On-Target plus, SmartPool
sequence-based reagent	TP53	371502118c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDKN1A	310832423c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB1	356582356c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB2	332205979c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDK1	281427275c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	MCM2	33356546c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	RPS15A	71772358c2	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	GAPDH	Hs.PT.45.8326	IDT Integrated DNA technologies, Coralville, IA	Expression level
commercial assay or kit	EdU	Click-it Plus EdU Imaging Kit	Life Technologies	
software, algorithm	Prism v7 and v8		GraphPad Software	

Study subjects

Written informed consent was obtained for HLHS probands and family members under a research protocol approved by the Mayo Clinic Institutional Review Board. Cardiac anatomy was assessed by echocardiography. Candidate genes were identified and prioritized by WGS of genomic DNA and RNA sequencing of patient-specific iPSC and cardiomyocytes. Methods for genomic analyses, RNA Sequencing, iPSC technology,

605   bioinformatics and statistics are described in the Online Appendix. Data are available at
606   NCBI GEO database.

609   **WGS and bioinformatic strategies**

610   Our methods for family phenotyping, WGS, variant filtering, and candidate gene
prioritization in the rare HLHS-CHD family and 25 HLHS proband-parent trios have been
previously described [7, 9, 18]. In brief, WGS of DNA isolated from blood or cheek swabs
was performed on a HiSeq 4000 platform at the Mayo Clinic Medical Genome Facility.
BAM files underwent primary and secondary analyses using an established workflow with
standard data quality metrics, and reads were aligned to the human hg38 reference
genome. Variant call format files with single nucleotide variants and small insertion-
deletion (indel) calls were analyzed using Ingenuity Variant Analysis software and
knowledge database (Qiagen). To retain only high-confidence data, variants were
required to have a base call quality of at least 20 and to pass Variant Quality Score
Recalibration. Functionally annotated coding and regulatory variants underwent primary
filtering and prioritization by an iterative approach with variants required to have a minor
allele frequency (MAF) <0.01 across all races in gnomAD v2.1.[93] Variants predicted to
impact protein structure were retained and included missense, frameshift, stop-gain, stop-
loss, canonical splice and non-canonical variants predicted to disrupt splicing based upon
MaxEntScan[94]. Regulatory variants were defined as those that (a) impact a microRNA
or microRNA binding site (b) reside in an enhancer binding site annotated in the VISTA
database (http://enhancer.lbl.gov/) or (c) disrupt a predicted promoter or transcription
factor binding site informed by the position-weighted matrices available in JASPAR
(http://jaspar.cgb.ki.se/). Genes harboring a rare functional variant were further required
to have upper quartile cardiac expression during mouse embryonic (e14.5) (Homsy et al.,
2015) or human fetal heart development (ranked percentiles from RNASeq experiments
available in ENCODE: ENCSR047LLJ (120 day male); ENCSR863BUL (91 day female);
ENCSR000AEZ (28 week female and 19 week female) (Davis et al., 2018).
For the HLHS-CHD family, a secondary segregation filter was applied to model autosomal
dominant inheritance with incomplete penetrance, which required sharing of prioritized

rare variants between affected family members. For the poor-outcome HLHS proband-
parent trios, a secondary Mendelian filter was applied to identify major-effect driver
variants that arose *de novo* or fit recessive modes of inheritance (i.e., homozygosity,
hemizygosity, compound heterozygosity).

To determine whether certain gene networks were over-represented, two online
bioinformatics tools were used. First, STRING[39] was used to investigate experimental
and predicted protein-protein and genetic interactions, and clustering of RP genes was
demonstrated when the highest stringency filter was applied. In addition, PANTHER[38]
was employed to identify potential enrichment of genes by ontology classification.

Generation of hPSC-VCMs

Id1 overexpressing hPSCs [33, derived from, 95] were dissociated with 0.5 mM
EDTA (ThermoFisher Scientific) in PBS without $CaCl_2$ and $MgCl_2$ (Corning) for 7 min at
room temperature. hPSC were resuspended in mTeSR-1 media (StemCell Technologies)
supplemented with 2 µM Thiazovivin (StemCell Technologies) and plated in a Matrigel-
coated 12-well plate at a density of 3 x 10^5 cells per well. After 24 hours after passage,
cells were fed daily with mTeSR-1 media (without Thiazovivin) for 3-5 days until they
reached ≥ 90% confluence to begin differentiation. hPSC-VCMs were differentiated as
previously described [95]. At day 0, cells were treated with 6 µM CHIR99021 (Selleck
Chemicals) in S12 media [96]. for 48 hours. At day 2, cells were treated with 2 µM Wnt-
C59 (Selleck Chemicals), an inhibitor of WNT pathway, in S12 media. 48 hours later (at
day 4), S12 media is fully changed. At day 5, cells were dissociated with TrypLE Express
(Gibco) for 2 min and blocked with RPMI (Gibco) supplemented with 10% FBS (Omega
Scientific). Cells were resuspended in S12 media supplemented with 4 mg/L
Recombinant Human Insulin (Gibco) (S12+ media) and 2 µM Thiazovivin and plated onto
a Matrigel-coated 12-well plate at a density of 9 x 10^5 cells per well. S12+ media was
changed at day 8 and replaced at day 10 with RPMI (Gibco) media supplemented with
213 µg/µL L-ascorbic acid (Sigma), 500 mg/L BSA-FV (Gibco), 0.5 mM L-carnitine
(Sigma) and 8 g/L AlbuMAX Lipid-Rich BSA (Gibco; CM media). Typically, hPSC-ACMs
start to beat around day 10. At day 15, cells were purified with lactate media (RPMI

without glucose, 213 µg/µL L-ascorbic acid, 500 mg/L BSA-FV and 8 mM Sodium-DL-

Lactate (Sigma), for 4 days. At day 19, media was replaced with CM media.

siRNA transfection, proliferation assay and immunostaining in hPSC-VCMs

At day 25 of differentiation, hPSC-VCMs were dissociated with TrypLE Select 10X

(Gibco), 10 min and neutralized with RPMI supplemented with 10% FBS. Cells were

resuspended in RPMI with 2% KOSR (Gibco) and 2% B27 50X with vitamin A (Life

Technologies) supplemented with 2 µM Thiazovivin and plated at a density of 5,000

cells/well in a Matrigel-coated 384-well plate. hPSC-VCMs were transfected with siRNA

(Dharmacon: ON-TARGETplus, custom RNAi cherry-pick libraries 0.1 nmol). For the

whole genome screening, siRNAs directed to 18,000 human genes were purchased from

the Genomic Center Facility at SBP at a final concentration of 25 nM using lipofectamine

RNAiMax (ThermoFisher) and opti-MEM (Gibco). 48 hours post-transfection, cells were

labelled with 10 µM EdU (ThermoFisher). After 24h of EdU incubation, cells were fixed

with 4% paraformaldehyde for 30 min and blocked in blocking buffer (10% Horse Serum,

10% Gelatin and 0.5% Triton X-100) for 20 min. EdU was detected according to protocol

and cells were stained with cardiac specific marker ACTN2 (A7811, Sigma, dilution

1/800), secondary antibody Alexa Fluor 568 (Invitrogen, 1/500) and DAPI (1/1000) in

Blocking Buffer. Cells were imaged with ImageXpress Micro XLS microscope (Molecular

Devices) and custom algorithms were used to quantify % of EdU+ ACTN1+ hPSC-VCMs

and the number of ACTN1+ cells. To quantify TP53 levels in hPSC-VCMs, cells were

stained with Phospho-p53 (700439, ThermoFisher, 1/500), counterstained with ACTN1

(anti-mouse A7811, Sigma, or anti-rat ab50599, Abcam), and imaged and quantified with

ImageXpress microscope. Whole genome screening was performed in one-replicate. All

the other siRNAs experiments were performed in quadruplicates.

RNA-seq and data analysis

hPSCs and hPSC-derived CMs were transfected with 25nM final concentrations of siRNA

against RPS15A, RPL39 and with scrambled control siRNAs as above. 2 days after

siRNA transfection RPs KD were verified and confirmed by proliferation assay (see

above), and cells were pelleted and resuspended in 500µl TRIzol reagent followed by

total RNA extraction. Library preparation and sequencing of the samples was done at La

Jolla Institute of Immunology (La Jolla, CA). FASTQ files were processed using nf-

core/rnaseq (version 21.03.0.edge [97]). Differential gene expression was determined

using R/DESeq2 [98] and GO term enrichment was done using gprofiler2[99]. Analysis

scripts can be downloaded at github.com/gvogler. Raw reads and counts tables are

available at GEO accession number GSE207658.

Proliferation assay in parent/proband iPSCs

hPSCs were dissociated as described previously and plated in a Matrigel-coated

384-well plate at a density of 3,000 cells per well. Cells were transfected with siRNA at a

final concentration of 25nM using lipofectamine RNAiMax and opti-MEM. After 3 days,

cells were labelled with 10 µM EdU for 1 hour. Cells were fixed with 4% paraformaldehyde

for 30 min and blocked in blocking buffer for 20 min. EdU was detected according to the

protocol and stained with stem cell specific marker OCT4 (P0082, Sigma, 1/500),

secondary antibody Alexa Fluor 568 and DAPI in Blocking Buffer. Cells were imaged with

ImageXpress microscope and % of EdU+ cells and number of OCT4+ cells were

quantified.

Quantitative Real Time PCR (RT-qPCR) in parent/proband iPSCs and hPSC-CMs

Total RNA was extracted using TRIzol and chloroform. 1ug of RNA was converted

in cDNA using QuantiTect Reverse Transcription kit (Qiagen). qRT-PCR was performed

using SYBR green (Biorad). Human primers sequences for qRT-PCR were obtained from

Harvard Primer Bank: TP53 (Primer Bank ID: 371502118c1), CDKN1A (Primer Bank ID:

310832423c1), CCNB1 (Primer Bank ID: 356582356c1), CCNB2 (Primer Bank ID:

332205979c1), CDK1 (Primer Bank ID: 281427275c1), MCM2 (Primer Bank ID:

33356546c1), RPS15A (Primer Bank ID: 71772358c2). All values were normalized to

GAPDH (Primer Bank ID: 378404907c1). At least 3 independent biological replicates

were performed for each experiment.

Statistical analysis

723   To determine any statistical significance between experimental and control groups

724   in hPSC-VCMs and iPSCs from parent/proband trio, we calculated two-sided p values

725   with Student's t-test using GraphPad Prism 8.1.2 software.

Drosophila heart function studies

Drosophila orthologs were determined using the DIOPT database [100], and fly

stocks were obtained from the Vienna Drosophila Resource Center (VDRC) stock center

or Bloomington Drosophila Stock Center (BDSC) as indicated in the key source table. For

in vivo functional heart analysis, we developed a high-throughput method based on

genetically modified flies with cardiomyocyte-specific RFP fluorescence (Klassen et al.).

The reporter line by itself or combined with the heart-specific *Hand*$^{4.2}$-Gal4 driver

(including all cardioblasts/cardiomyocytes, pericardial cells and wing hearts throughout

development starting at post-mitotic, mid-embryonic stages through adulthood [101-103]

was crossed to UAS-lines or mutant flies. For interaction studies a fly line harboring the

fluorescent reporter, *Hand*$^{4.2}$-Gal4 driver and a Deficiency for RpS15Aa was generated.

Adult progeny flies were immobilized and exposed to fluorescence light to record 5 sec

high frame rate movies of the beating heart. Movies were analyzed by fully automated

quantification of contractility and rhythmicity parameters of the heart [104]. Semi-intact

adult fly hearts were filmed and analyzed according to standard protocol [27, 105].

Immunostainings of the fly heart

The immunostaining of fly adult hearts was performed as described previously

[106]. In short, adult flies were dissected in a semi-intact fashion to expose the heart

according to protocol [27, 107]. Myofibrils were relaxed using 10mM EGTA followed by

fixation in 4% formaldehyde for 15 min. Hearts were washed with PBS + Triton (PBT;

0.03 % triton X-100) and stained using Alexa 647 phalloidin (Life Technologies) 2h at

room temperature (RT). For Mhc labelling, hearts were stained using anti-Mhc antibody

(1:50, incubation over night at 4°C) and after three washes with PBT, secondary antibody

was applied for 2 h at RT. Hearts were washed with PBT three times and PBS one time

and mounted using ProLong Gold mountant with DAPI (Life Technologies). Heart

preparations were imaged with the Imager.Z1 with an Apotome (Carl Zeiss), Hamamatsu

Orca Flash 4.0 and ZEN imaging software (Carl Zeiss).

Zebrafish Husbandry

All zebrafish experiments were performed in accordance with protocols approved

by IACUC. Zebrafish were maintained under standard laboratory conditions at 28.5°C. In

addition to Oregon AB wild-type, the following transgenic lines were used:

Tg(myl7:EGFP)^{twu277} [108] and *Tg(myl7:H2A-mCherry)^{sd12}* [109].

In zebrafish, gene expression was manipulated using standard microinjection of

morpholino (MO) antisense oligonucleotides [110]. In addition, we performed targeted

mutagenesis using CRISPR/Cas9 genome editing[111-113], to create insertion/deletion

(INDEL) mutations in relevant ribosomal genes (F0). Subsequently, zebrafish were raised

to 72 hours post fertilization (hpf), immobilized in low melt agarose and the hearts were

filmed and analyzed according to standard protocol[27].

MO sequence information:

All MOs were purchased from Gene Tools, LLC, synthesized at 300nmol, except

zebrafish p53 oligos at 100nmol.

Zebrafish *rpl13* 5'-UTR MO: TTGTTCACTCCGTCCTTAGCGGAAA

Zebrafish *rps15a* 5'-UTR MO: CGCACCATGATGCCAGTTCTGCAAT

Zebrafish *rpl39* 5'-UTR MO: GGATCGCAATCCGTTCACCACTATG

Zebrafish p53 MO: GCGCCATTGCTTTGCAAGAATTG

Zebrafish Control MO: 5'-CCT CTT ACC TCA GTT ACA ATT TAT A-3'.

Zebrafish SOHA (Semi-automated Optical Heartbeat Analysis)

Larval zebrafish (72 hpf) were immobilized in a small amount of low melt agarose

(1.5%) and submerged in conditioned water. Beating hearts were imaged with direct

immersion optics and a digital high-speed camera (up to 200 frame/sec, Hamamatsu

Orca Flash) to record 30 seconds movies; images were captured using HC Image

(Hamamatsu Corp.). Cardiac function was analyzed from these high-speed movies using

semi-automatic optical heartbeat analysis software[27, 114], which for zebrafish

quantifies heart period (R-R interval), cardiac rhythmicity, as well as chamber size and

fractional area change. All hearts were imaged at room temperature (20-21°C). Statistical

analyses were performed using Prism software (Graphpad). Significance was determined

using two-tailed, unpaired student t-test or one-way ANOVA and Dunnett's multiple

comparisons post hoc test as appropriate.

Zebrafish Cardiomyocyte Cell Counts and Cardiac immunofluorescent imaging

To count cardiomyocytes, we used the expression of H2AmCherry in the nuclei

(*Tg(myl7:H2A-mCherry*)[109] to qualify as an individual cell, performed the "Spot" function

in Imaris to distinguish individual cells in reconstructions of confocal z-stacks.[115, 116]

To compare data sets, we used Prism software (GraphPad) to perform Student's t-test

with two-tail distribution. Graphs display mean and standard deviation for each data set.

Whole-mount immunofluorescence was performed as previously described[18,

115-117] (see also key resources table). Confocal imaging was performed on an LSM

710 confocal microscope (Zeiss, Germany) with a 40x water objective. Exported z-stacks

were processed with Imaris software (Bitplane), Zeiss Zen, and Adobe Creative Suite

software (Photoshop and Illustrator 2020). All confocal images shown are projection

views of partial reconstructions from multiple z-stack slices, except where noted that

images are views of a single slice.

For proliferation assays, embryos at 24, 48, and 72 hpf were fixed in 4%

paraformaldehyde overnight at 4 °C, washed in PBS with 0.1% Tween-20 (PBST).

Samples were blocked in 5% normal goat serum in PBST prior to incubation with primary

antibodies. Proliferating cells were labeled with anti-phospho-histone H3 (Sigma Aldrich-

H0412 PH3; 1:500) and total nuclei were counterstained with DAPI. Embryos were

mounted in ProLong Gold for imaging. Whole-mount hearts were imaged on a Zeiss

Apotome microscope at 10× magnification. Z-stacks were acquired and reconstructed

using Fiji/ImageJ. Regions corresponding to atrium, ventricle, atrioventricular canal, and

outflow tract were manually segmented. For some experiments, cardiomyocyte nuclei

were identified based on Tg(myl7:H2A-mCherry) expression, with DAPI used to quantify

total cell counts. For proliferation experiments DAPI was used to identify cardiac cells and

proliferating cells were identified by PH3 staining. Proliferative indices were calculated as

PH3+/DAPI+ ratios from z-stacks analyzed in Fiji/ImageJ using the Cell Counter plugin.

Cell counts were performed on at least 10 embryos per condition per timepoint.

Zebrafish CRISPR/Cas9 experiments

Detailed steps were previously described[118] and we followed IDT manufacture

instruction for Complexes preparation. crRNA:tracrRNA Duplex Preparation: Target-

specific Alt-R® crRNA (sequence information see below) and common Alt-R® tracrRNA

were synthesized by IDT and each RNA was dissolved in duplex buffer (IDT) as 100 µM

stock solution. Stock solutions were stored at -20°C. To prepare the crRNA:tracrRNA

duplex, equal volumes of 100 µM Alt-R® crRNA and 100µM Alt-R® tracrRNA stock

solutions were mixed together and annealed by heating followed by gradual cooling to

room temperature by manufacture instruction: 95°C, 5 min on PCR machine; cool to

25°C; cool to 4°C rapidly on ice. The 50 µM crRNA:tracrRNA duplex stock solution was

stored at -20°C. Preparation of crRNA:tracrRNA:Cas9 RNP Complexes: Cas9 protein

(Alt-R® S.p. Cas9 nuclease, v.3, IDT) was adjusted to 25 µM stock solution in 20mM

HEPES-NaOH (pH 7.5), 350 mM KCl, 20% glycerol, dispensed as 8 ul aliquots, and

stored at -80°C. 25µM crRNA:tracrRNA duplex was produced by mixing equal volumes

of 50 µM crRNA:tracrRNA duplex stock and duplex buffer (IDT). We used 5 µM RNP

complex. To generate 5µM crRNA:tracrRNA:Cas9 RNP complexes: 1 µl 25 µM

crRNA:tracrRNA duplex was mixed with 1 µl 25 µM Cas9 stock, 2 µl H2O, and 1 µl 0.25%

phenol red solution. Prior to microinjection, the RNP complex solution was incubated at

37°C, 5 min and then placed at room temperature. Approximately one nanoliter of 5 µM

RNP complex was injected into the cytoplasm of one-cell stage embryos to generate F0

larva.

IDT crRNA sequence information:

All crRNAs were purchased from Integrated DNA Technologies, Inc., synthesized

at 2 nmol with standard desalting condition.

Dr.Cas9.RPS15A.1.AC: /AltR1/rUrU rGrUrU rGrUrC rArArU rCrUrC rArCrA rGrGrG

rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

Dr.Cas9.RPS15A.1.AB: /AltR1/rGrC rGrUrA rCrUrA rUrGrA rCrUrU rUrArG rArGrC

rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

Dr.Cas9.RPS17.1.AC:

/AlTR1/rUrGrArCrUrUrCrCrArCrArUrUrArArCrArArGrCrGrUrUrUrUrArGrArGrCrUrArUrG

rCrU/AlTR2/

Dr.Cas9.RPS28.1.AA:

/AlTR1/rCrUrGrGrGrArArArGrArArArCrUrGrGrCrUrCrCrCrArGrUrUrUrUrArGrArGrCrUrArUr

GrCrU/AlTR2/

Competing interests: None.

Table 1: Table 1 – Variants in ribosomal genes in HLHS probands. Abbrevations:
MAF – minor allele frequency; TFBS – transcription factor binding site; n.t. – not tested;
ASD – atrial septal defect; PLE - Protein-losing enteropathy; RV – right ventricle; RVEF
– right ventricular ejection fraction; RVEDP - right ventricular end diastolic pressure

Figure 1: Whole Genome siRNA Screen identified Ribosomal proteins as agonists
of cardiomyocyte proliferation. (A) High-throughput iPSC-derived CM proliferation
screen overview. **(B)** Screen result showing normalized % EdU+ CMs (X-axis) and
relative total number of CMs (Y-axis) upon knockdown of genome-wide siRNAs (18,055
siRNAs). siRNAs for RPL and RPS genes highlighted in red. **(C)** Representative
immunofluorescence images of proliferation (EdU incorporation, green, CM marker
ACTN2, red) of induced hPSC-CMs upon *TP53* and *RPS14* knockdown. Insets: nuclei
(DAPI) **(D)** Gene ontology enrichment analysis for WGS hits (BP, biological process;
FDR-corrected analysis using gprofiler2). (**E**) Overview of hits corresponding to top 4 non-
redundant BP categories.

Figure 2: Ribosomal gene variants identified in HLHS. (A) Gene prioritization scheme
of 25 poor-outcome proband-parent trios. **(B)** Testing 292 HLHS candidate genes from
all poor-outcome families in CMs identified RPs as major regulators of hPSC-CM
proliferation (Normalized fraction of ACTN2+/EdU+ cells). **(C)** *Drosophila* cardiac
phenotypes induced by loss of RP genes affected in HLHS patients with poor outcome.
Heart is visualized by RFP expression specifically in cardiomyocytes (R94C02::tdTom).
Knockdown is achieved by sustained Gal4/UAS activity using Hand4.2-Gal4. (**D**) Wild-
type zebrafish larva, *rps17* and *rps28* CRISPR mutants and *rpl39* morphants at 72 hpf.
rpl39 morphants, injected with 1 ng MO in lateral view, show mild edema. **(E)** Systolic
surface area (SA) upon *rps17* and *rps28* CRISPR, and diastolic SA after *rpl39* MO in the
atrium and ventricle of zebrafish hearts.

Figure 3: Characterization of RPS15A from 75H HLHS index family. (A) (B) (C)
Prioritized candidate genes from the 75H family and relative hPSC-CM proliferation
capacity upon KD. (**D**) Representative immunofluorescence images of proliferation (EdU

incorporation, green; CM marker ACTN2, red) of induced hPSC-CMs upon siRPS15A

knockdown. **(E)** Heart-specific KD of *RpS15Aa* in *Drosophila* adult hearts cause loss of

heart tissue and is fully penetrant. **(F)** Representative immunofluorescence images of

control and *RpS15Aa*-RNAi shows partial heart loss (Myosin heavy chain, Mhc, red; heart

tissue-reporter, green). **(G)** CRISPR-mediated loss of *rps15a* in F_0 larval zebrafish hearts

causes decrease in CM number. **(H)** Representative immunofluorescence of hearts and

whole-mount images of control and *rps15a*-CRISPR F_0 larval hearts (CM nuclei reporter,

red).

898
899
Figure 4*:* **Loss of ribosomal gene function in CMs invokes TP53-stress response**.

(A) RNA sequencing of hPSC-CMs following siRNA-treatment for *RPL39* and *RPS15A*

shows both, convergent and divergent transcriptomic response. **(B)** GO term analysis of

differentially expressed genes following RP KD shows TP53-mediated response,

including upregulation of *CDKN1A*. **(C, D)** CDKN1A is highly upregulated in CMs following

siRPS15A treatment. **(E, F)** Reduced CM proliferation upon *RPS15A* KD is mediated by

CDKN1A/*TP53* and can be rescued upon their co-KD. **(G, H)** Larval zebrafish CM number

is reduced by morpholino-treatment for rps15a and can be attenuated by P53 morpholino

co-injection. Control and morphant (MO) hearts of 72 hpf zebrafish larva stained with

Tg(myl7:EGFP) and *Tg(myl7:H2A-mCherry)*. Note that smaller heart with aberrant

looping by *rps15a* MO is partially reversed by *p53* co-KD. Student's t-test, *p<0.05,

p<0.01, ***p<0.001, ****p<0.0001.**

Figure 5: Rescue of *RpS15Aa* KD-mediated heart tube loss in Drosophila by

YAP/yorkie overexpression depending on its co-factor TEAD/scalloped. (A)

Representative images of RFP expressing fly hearts. RpS15Aa KD-mediated heart tube

loss can be partially rescued by overexpression of *yorkie* (*RpS15Aa* RNAi + *yorkie* OE) .

The rescue by *yki* OE depends on its co-factor *sd*. Flies were raised at 25 °C. **(B)**

Quantification of events presented as a percentage of flies exhibiting whole heart tube

versus partial heart loss (defined as 25-75% heart tube length compared to wildtype) or

no heart tube. Statistics: Fisher's exact test, *p<0.05. **(C)** Proposed signaling cascade

underlying cardiac growth, proliferation and differentiation impairment following ribosomal
stress (adapted from Baker et al., 2019).

Figure 6: *RPS15A* genetically interacts with cardiac transcription factors. (A) The
majority of cardiac transcription factors do not impact CM proliferation, except for e.g.,
HES4 and HOPX. **(B)** *TBX5* genetically interacts with *RPS15A* and *RPL39*. *siTBX5* does
not impact CM proliferation at 0.5, 1, 1.5 or 2nM si-concentration, and neither do
siRPS15A and *siRPL39* alone at 0.5nM. CM proliferation is reduced in siRP backgrounds
with increased titration of *siTBX5*. Two-way ANOVA for si*TBX5* dosage, RP-knockdown
and their interaction. **(C)** Representative fly heart segment (A4) from control flies,
heterozygous mutants (*tin*[346/+], *pnr*[VX6/+], *Doc*[Df/-], *Df(RpS15Aa)* [+/-]) and transheterozygous
mutants. *tin*[+/-] = *tin*[346]/+, pnr[+/-] = *Df(pnr)*/+ , Doc[+/-] = *Df(DocA)*/+. Note the deformation and
myofibrillar disorganization in the transheterozygous mutants. **(D)** Quantification of adult
Drosophila heart defects and genetic interaction. - Statistics: Fisher's exact test on
absolute numbers testing *normal* vs. *severely deformed* hearts. *p<0.05, **p<0.005,
***p<0.001.

Figure 7: RP-dependent cardiac-specific regulation of cell proliferation. (A)
Schematic illustrating approach to identify novel RP-dependent and cardiac-specific
HLHS-associated gene network controlling CM proliferation. **(B)** Heatmap showing
differential expression (hiPSC-CMs vs hiPSCs) of genes regulating CM proliferation. **(C)**
Histogram showing effect of cardiac-specific and HLHS-associated genes on CM
proliferation. **(D)** Visualization of RP-dependent and cardiac-specific HLHS-associated
gene network (GeneMania). HLHS families. **(E)** Table of HLHS families harboring rare
and damaging variant in RP-dependent and cardiac-specific genes. **(F)** Histogram
showing lack of effect of siEWSR1 on OCT4+ hiPSCs. **(G)** Representative images of
OCT4+ cells in siControl and siEWSR1. **(H)** Histogram showing that siEWSR1 increases
the % of CDKN1A+ CMs as compared to siControl. **(I)** Histogram showing that siEWSR1
concomitantly decreases the % of EDU+ CMs as compared to siControl. **(J)**
Representative images showing immunostaining for CDKN1A (white), EDU (green) and

ACTN2 (Red) in siEWSR1 an siControl condition. **(K)** Pathway reconstruction of cardiac

and RP-dependent regulation of CM proliferation by HLHS-associated genes. Chi-square

test, *p<0.05, **p<0.005, ***p<0.001

Figure 8: Model for RP-dependent involvement in HLHS-associated phenotypes.

Schematic showing that combined prioritization and unbiased screening led to the

identification of a novel HLHS-associated gene network regulating CM proliferation as

potential disease-causing mechanism.

Supplemental Figure 1: (A, B) Confirmatory siRNA screening for all RP genes confirms

critical role for RPs in CM proliferation. **(C, D)** KD of RPs reduces proliferation in human

fibroblasts.

Supplemental Figure 2: Model organism phenotypes caused by loss of RP genes.

(A) Pedigree of the extended 75H family investigated for shared variants between HLHS

proband (black square) and distant cousin with CHD (half-filled circle). **(B) (C)** Diastolic

and **(D)** and Systolic Surface Area after rps15a CRISPR. Statistics: Mann-Whitney test,

*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Supplemental Figure 3: *rps15a* zebrafish larval morphants show heart dysfunction

and reduction in cardiomyocyte number. (A) Lateral view (head to the right) of a wild-

type control zebrafish larva (top) and a morphant (bottom) following injection of 2 ng/µl

rps15a morpholino (MO). The morphant exhibits near normal body/tail but notable

pericardial edema (arrowhead). **(B)** Control (left) and morphant hearts (right) stained with

Tg(*myl7*:EGFP) and Tg(*myl7*:H2A-mCherry). Note the smaller heart with aberrant looping

in morphant heart. **(C)** Total CM counts (mCherry+ cells) in control and *rps15a* morphants

shown in (B). **(D)** Fractional area change (FAC) in control and *rps15a* morphants. **(E-H)**

Injection of Control MO had little effect on zebrafish cardiac function. There was no

significant difference between uninjected and injected controls with respect to **(E)** Systolic

or (**F**) Diastolic Surface Areas, (**G**) Fractional Area Change or (**H**) R-R intervals. Student's

t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Supplemental Figure 4: Proliferation and heart function depends on RPS15A and

is regulated via TP53 in CMs and zebrafish. (A-C) Cardiac proliferation (by PH3, **A**),

total CM number (DAPI, **B**) and ratio of proliferating CMs (C) assessed for *rps15a*

morphants (KD) and CRIPSR (KO) for three timepoints, 24/48/72hpf **(D, E)** The number

of *siRPS15A*-treated CMs is strongly reduced, which can be attenuated by co-KD of

CDKN1A or *TP53*. **(F,G)** Loss of *rps15a* causes strong reduction in zebrafish heart

contractility (measured by Fractional Area Change, **C**) and heart period **(D)**, which can be

rescued by co-KD of *p53* in both, zebrafish heart atrium and ventricle.

Supplemental Figure 5: Genetic interaction between *RpS15Aa/RPS15A* and

***cabeza/EWSR1* (A, B)** Dose-dependent inhibition of hPSC-CMs proliferation by RPS15A

KD. **(C)** Diastolic Diameter (DD), and Heart Period (HP) of 3-week-old female control and

heterozygous RpS15Aa deficient flies with or without additional heterozygous mutation in

tinman, pannier or Dorsocross. Statistics: Kruskal-Wallis, *p<0.05, **p<0.005, ***p<0.001,

****p<0.0001. Note, the prolonged HP in transheterozygous mutants for Df(RpS15Aa)

and tinman. **(D, E)** FAC, and HP of the atria and ventricles at 72 hpf in zebrafish embryos

injected with 0.5 ng rps15a and/or 1 ng nkx2.7 MOs (**E**) or 0.5 ng rps15a and/or 0.5 ng

tbx5 MOs (F**).** Note, that FAC and heart periods show synergistic genetic interaction

between rps15a and nkx2.7 and tbx5a. Statistics: 2-Way ANOVA, *p<0.05, **p<0.01,

****p<0.0001.**(F)** Systolic intervals (SI) of 1-week-old adult flies upon heart-specific

knockdown of *cabeza* (*caz^{32990}* or *caz^{34839}* RNAi) using Hand^{4.2}-Gal4 driver with or without

additional RpS15Aa heterozygosity (RpS15Aa^{Df/+}) and age-matched controls. Automated

analysis of SI depicted as median with interquartile range obtained from 5s high-frame-

rate videos. Statistics: Kruskal-Wallis test, *p<0.05, **p<0.01, ***p<0.001.

1007

Suppl. Fig. 6: RpS15Aa KD induces nucleolar stress in 3rd instar larval hearts. (A)

Nucleolar stress induction in 3rd instar larval hearts upon *RpS15Aa* KD as indicated by

enlarged nucleoli. Hearts from control and *RpS15Aa* KD. 3rd instar larva stained for F-

Actin (red), DAPI (blue), and nucleolus marker Fibrillarin (green) and cardiomyocyte (CM)

nuclei in magnifications. Note, heart constriction upon *RpS15Aa* KD in the larval heart.

(B) Quantification of nucleolus area and area ratio(nucleolus/nucleus) indicates

significantly enlarged nucleoli upon *RpS15Aa* KD. Statistics: Mann-Whitney test,

****p<0001. **(C)** Schematic representation of different nucleolar phenotypes upon RNAi-

mediated loss of function. **(D)** As a positive control, KD of another nucleolar key player

Nopp140 specifically in the heart using Hand$^{4.2}$-Gal4 combined with Fibrillarin^{EGFP} (kind

gift of the Wieschaus lab) leads to loss of nucleolar maintenance. 3rd instar larva stained

for F-Actin (red) and DAPI (blue). Fibrillarin in (green). Cardiomyocyte nuclei in

magnifications. PC= Pericardial Cell

1021

1022

Supplemental Table 1: Whole genome siRNA screen results table.

Supplemental Table 2: 292 filtered variants from poor-outcome HLHS probands.

MOI – mode of inheritance

Supplemental Table 3: Subset from all 292 genes that cause CM proliferation

defects and/or fly heart defects

Supplemental Table 4: Segregating variants of 75H proband.

Supplemental Tables 5-8: Differential gene expression lists for siRPL39 and

siRPS15A in hPSCs and CMs.

Supplemental Table 9: 12 genes prioritized after RNAseq and WGS analysis.

1032

1033

1034

1035

1036

REFERENCES

1.   Gordon BM, Rodriguez S, Lee M, Chang R-K. Decreasing number of deaths of infants with hypoplastic left heart syndrome. J Pediatr. 2008;153(3):354-8. doi: 10.1016/j.jpeds.2008.03.009.

2.   Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153(6):807-13. doi: 10.1016/j.jpeds.2008.05.059.

3.   Crucean A, Alqahtani A, Barron DJ, Brawn WJ, Richardson RV, O'Sullivan J, et al. Re-evaluation of hypoplastic left heart syndrome from a developmental and morphological perspective. Orphanet J Rare Dis. 2017;12(1):138. doi: 10.1186/s13023-017-0683-4.

4.   Konno Y, Toki T, Tandai S, Xu G, Wang R, Terui K, et al. Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica. 2010;95(8):1293-9. doi: 10.3324/haematol.2009.020826.

5.   Agopian AJ, Goldmuntz E, Hakonarson H, Sewda A, Taylor D, Mitchell LE, et al. Genome-Wide Association Studies and Meta-Analyses for Congenital Heart Defects. Circ Cardiovasc Genet. 2017;10(3):e001449. doi: 10.1161/CIRCGENETICS.116.001449.

6.   Martin LJ, Pilipenko V, Benson DW. Role of Segregation for Variant Discovery in Multiplex Families Ascertained by Probands With Left Sided Cardiovascular Malformations. Front Genet. 2018;9:729. doi: 10.3389/fgene.2018.00729.

7.   Theis JL, Hrstka SCL, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, et al. Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome. Hum Genet. 2015;134(9):1003-11. doi: 10.1007/s00439-015-1582-1.

8.   Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, et al. Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J Am Coll Cardiol. 2003;41(11):2072-6. doi: 10.1016/s0735-1097(03)00420-0.

9.   Theis JL, Zimmermann MT, Evans JM, Eckloff BW, Wieben ED, Qureshi MY, et al. Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction. Circ Cardiovasc Genet. 2015;8(4):564-71. doi: 10.1161/CIRCGENETICS.115.001070.

10.   Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, et al. SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet. 2017;26(13):2412-25. doi: 10.1093/hmg/ddx132. PubMed PMID: 28379402.

11.   Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH. Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res. 2001;479(1-2):173-86. doi: 10.1016/s0027-5107(01)00160-9.

12.   Yagi H, Liu X, Gabriel GC, Wu Y, Peterson K, Murray SA, et al. The Genetic Landscape of Hypoplastic Left Heart Syndrome. Pediatr Cardiol. 2018;39(6):1069-81. doi: 10.1007/s00246-018-1861-4. PubMed PMID: 29569026.

13.   Yaich L, Ooi J, Park M, Borg JP, Landry C, Bodmer R, et al. Functional analysis of the Numb phosphotyrosine-binding domain using site-directed mutagenesis. The Journal of biological chemistry. 1998;273(17):10381-8. PubMed PMID: 9553095.

14.   Grossfeld P, Ye M, Harvey R. Hypoplastic left heart syndrome: new genetic insights. J Am Coll Cardiol. 2009;53(12):1072-4. doi: 10.1016/j.jacc.2008.12.024. PubMed PMID: 19298922.

15.   Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, et al. Intrinsic Endocardial Defects
Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell. 2020;27(4):574-89.e8. doi:
10.1016/j.stem.2020.07.015.
16.   Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, et al. The complex genetics of
hypoplastic left heart syndrome. Nat Genet. 2017;49(7):1152-9. doi: 10.1038/ng.3870.
17.   Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, et al. Fetal reprogramming
and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during
cardiac differentiation. Am J Pathol. 2013;183(3):720-34. doi: 10.1016/j.ajpath.2013.05.022.
18.   Theis JL, Vogler G, Missinato MA, Li X, Nielsen T, Zeng X-XI, et al. Patient-specific
genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.
eLife. 2020;9:e59554. doi: 10.7554/eLife.59554.
19.   Bodmer R. The gene tinman is required for specification of the heart and visceral muscles
in Drosophila. Development. 1993;118(3):719-29.
20.   Bodmer R. Heart development in Drosophila and its relationship to vertebrates. Trends in
Cardiovascular Medicine. 1995;5(1):21-8. doi: 10.1016/1050-1738(94)00032-Q.
21.   Cripps RM, Olson EN. Control of cardiac development by an evolutionarily conserved
transcriptional network. Dev Biol. 2002;246(1):14-28. doi: 10.1006/dbio.2002.0666.
22.   Bodmer R, Frasch M. Chapter 1.2 - Development and Aging of the Drosophila Heart. In:
Rosenthal N, Harvey RP, editors. Heart Development and Regeneration. Boston: Academic Press;
2010. p. 47-86.
23.   Bier E, Bodmer R. Drosophila, an emerging model for cardiac disease. Gene.
2004;342(1):1-11. doi: 10.1016/j.gene.2004.07.018.
24.   Evans SM, Yelon D, Conlon FL, Kirby ML. Myocardial lineage development. Circ Res.
2010;107(12):1428-44. doi: 10.1161/CIRCRESAHA.110.227405.
25.   Bakkers J. Zebrafish as a model to study cardiac development and human cardiac disease.
Cardiovasc Res. 2011;91(2):279-88. doi: 10.1093/cvr/cvr098.
26.   Liu J, Stainier DYR. Zebrafish in the study of early cardiac development. Circ Res.
2012;110(6):870-4. doi: 10.1161/CIRCRESAHA.111.246504.
27.   Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A
new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and
embryonic mouse hearts. Biotechniques. 2009;46(2):101-13. doi: 10.2144/000113078.
28.   Huang G-Y, Xie L-J, Linask KL, Zhang C, Zhao X-Q, Yang Y, et al. Evaluating the role
of connexin43 in congenital heart disease: Screening for mutations in patients with outflow tract
anomalies and the analysis of knock-in mouse models. J Cardiovasc Dis Res. 2011;2(4):206-12.
doi: 10.4103/0975-3583.89804.
29.   Yu MS, Spiering S, Colas AR. Generation of First Heart Field-like Cardiac Progenitors
and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells. JoVE (Journal of
Visualized Experiments). 2018;(136):e57688. doi: 10.3791/57688.
30.   Paige SL, Galdos FX, Lee S, Chin ET, Ranjbarvaziri S, Feyen DAM, et al. Patient-Specific
Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left
Heart   Syndrome.   Circulation.   2020;142(16):1605-8.   doi:
10.1161/CIRCULATIONAHA.119.045317.
31.   Diez-Cunado M, Wei K, Bushway PJ, Maurya MR, Perera R, Subramaniam S, et al.
miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway. Cell
reports. 2018;23(7):2168-74. Epub 2018/05/17. doi: 10.1016/j.celrep.2018.04.049. PubMed
PMID: 29768213; PubMed Central PMCID: PMCPMC6261450.

32.   Murphy SA, Miyamoto M, Kervadec A, Kannan S, Tampakakis E, Kambhampati S, et al.
PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2. Nature
communications. 2021;12(1):1648. Epub 2021/03/14. doi: 10.1038/s41467-021-21957-z. PubMed
PMID: 33712605; PubMed Central PMCID: PMCPMC7955035.
33.   Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang C-T, et al. Id
genes are essential for early heart formation. Genes Dev. 2017;31(13):1325-38. doi:
10.1101/gad.300400.117.
34.   Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang CT, et al. Id genes
are essential for early heart formation. Genes & development. 2017. doi: 10.1101/gad.300400.117.
PubMed PMID: 28794185.
35.   Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2
oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and
chemotherapy. Proc Natl Acad Sci U S A. 2003;100(20):11636-41. Epub 2003/09/18. doi:
10.1073/pnas.1934692100.   PubMed   PMID: 13130078;   PubMed   Central   PMCID:
PMCPMC208810.
36.   Yuan LL, Green A, David L, Dozier C, Recher C, Didier C, et al. Targeting CHK1 inhibits
cell proliferation in FLT3-ITD positive acute myeloid leukemia. Leuk Res. 2014;38(11):1342-9.
Epub 2014/10/05. doi: 10.1016/j.leukres.2014.08.020. PubMed PMID: 25281057.
37.   Zhou X, Liao WJ, Liao JM, Liao P, Lu H. Ribosomal proteins: functions beyond the
ribosome. J Mol Cell Biol. 2015;7(2):92-104. Epub 2015/03/05. doi: 10.1093/jmcb/mjv014.
PubMed PMID: 25735597; PubMed Central PMCID: PMCPMC4481666.
38.   Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more
genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic
Acids Res. 2019;47(D1):D419-D26. doi: 10.1093/nar/gky1038.
39.   Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:
protein-protein association networks with increased coverage, supporting functional discovery in
genome-wide   experimental   datasets.   Nucleic   Acids   Res.   2019;47(D1):D607-D13.   doi:
10.1093/nar/gky1131.
40.   Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and
generating dominant phenotypes. Development. 1993;118(2):401-15.
41.   Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, et al. Fetal reprogramming
and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during
cardiac   differentiation.   Am J Pathol.   2013;183(3):720-34.   doi: 10.1016/j.ajpath.2013.05.022.
PubMed PMID: 23871585.
42.   Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, et al. The complex genetics of
hypoplastic   left   heart   syndrome.   Nature   genetics.   2017;49(7):1152-9.   doi: 10.1038/ng.3870.
PubMed PMID: 28530678.
43.   Schroeder AM, Allahyari M, Vogler G, Missinato MA, Nielsen T, Yu MS, et al. Model
system identification of novel congenital heart disease gene candidates: focus on RPL13. Hum
Mol Genet. 2019;28(23):3954-69. doi: 10.1093/hmg/ddz213.
44.   Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A
new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and
embryonic mouse hearts. Biotechniques. 2009;46(2):101-13. doi: 10.2144/000113078. PubMed
PMID: 19317655; PubMed Central PMCID: PMC2855226.

1174 45. Uechi T, Nakajima Y, Nakao A, Torihara H, Chakraborty A, Inoue K, et al. Ribosomal
1175 Protein Gene Knockdown Causes Developmental Defects in Zebrafish. PLOS ONE.
1176 2006;1(1):e37. doi: 10.1371/journal.pone.0000037.
1177 46. Ikeda F, Yoshida K, Toki T, Uechi T, Ishida S, Nakajima Y, et al. Exome sequencing
1178 identified RPS15A as a novel causative gene for Diamond-Blackfan anemia. Haematologica.
1179 2017;102(3):e93-e6. doi: 10.3324/haematol.2016.153932.
1180 47. Miura GI, Yelon D. A Guide to Analysis of Cardiac Phenotypes in the Zebrafish Embryo.
1181 Methods Cell Biol. 2011;101:161-80. doi: 10.1016/B978-0-12-387036-0.00007-4.
1182 48. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943-56.
1183 Epub 2017/03/14. doi: 10.1038/onc.2016.502. PubMed PMID: 28288132; PubMed Central
1184 PMCID: PMCPMC5511239.
1185 49. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, et al. p53 activation
1186 by knockdown technologies. PLoS Genet. 2007;3(5):e78. doi: 10.1371/journal.pgen.0030078.
1187 50. Furth N, Aylon Y, Oren M. p53 shades of Hippo. Cell Death Differ. 2018;25(1):81-92. doi:
1188 10.1038/cdd.2017.163.
1189 51. Baker NE, Kiparaki M, Khan C. A potential link between p53, cell competition and
1190 ribosomopathy in mammals and in Drosophila. Dev Biol. 2019;446(1):17-9. doi:
1191 10.1016/j.ydbio.2018.11.018.
1192 52. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, et al. Drosophila
1193 p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000;101(1):91-101.
1194 doi: 10.1016/S0092-8674(00)80626-1. PubMed PMID: 10778859.
1195 53. Raj N, Bam R. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family
1196 Proteins: Mechanisms and Outcomes in Cancer. Front Cell Dev Biol. 2019;7:159. Epub 20190809.
1197 doi: 10.3389/fcell.2019.00159. PubMed PMID: 31448276; PubMed Central PMCID:
1198 PMCPMC6695833.
1199 54. Monroe TO, Hill MC, Morikawa Y, Leach JP, Heallen T, Cao S, et al. YAP Partially
1200 Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo.
1201 Developmental Cell. 2019;48(6):765-79.e7. doi: 10.1016/j.devcel.2019.01.017.
1202 55. Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and
1203 human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther.
1204 2021;6(1):323. Epub 2021/09/01. doi: 10.1038/s41392-021-00728-8. PubMed PMID: 34462428;
1205 PubMed Central PMCID: PMCPMC8405630.
1206 56. Bruneau BG, Logan M, Davis N, Levi T, Tabin CJ, Seidman JG, et al. Chamber-specific
1207 cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Developmental biology.
1208 1999;211(1):100-8. doi: 10.1006/dbio.1999.9298. PubMed PMID: 10373308.
1209 57. Qian L, Wythe JD, Liu J, Cartry J, Vogler G, Mohapatra B, et al. Tinman/Nkx2-5 acts via
1210 miR-1 and upstream of Cdc42 to regulate heart function across species. J Cell Biol.
1211 2011;193(7):1181-96. doi: 10.1083/jcb.201006114. PubMed PMID: 21690310; PubMed Central
1212 PMCID: PMCPMC3216339.
1213 58. Lee KH, Xu Q, Breitbart RE. A new tinman-related gene, nkx2.7, anticipates the
1214 expression of nkx2.5 and nkx2.3 in zebrafish heart and pharyngeal endoderm. Dev Biol.
1215 1996;180(2):722-31. doi: 10.1006/dbio.1996.0341.
1216 59. Targoff KL, Schell T, Yelon D. Nkx Genes Regulate Heart Tube Extension and Exert
1217 Differential Effects on Ventricular and Atrial Cell Number. Dev Biol. 2008;322(2):314-21. doi:
1218 10.1016/j.ydbio.2008.07.037.

60. Tiu GC, Kerr CH, Forester CM, Krishnarao PS, Rosenblatt HD, Raj N, et al. A p53-
dependent translational program directs tissue-selective phenotypes in a model of
ribosomopathies. Developmental Cell. 2021;0(0). doi: 10.1016/j.devcel.2021.06.013.
61. McGowan KA, Pang WW, Bhardwaj R, Perez MG, Pluvinage JV, Glader BE, et al.
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.
Blood. 2011;118(13):3622-33. Epub 20110725. doi: 10.1182/blood-2010-11-318584. PubMed
PMID: 21788341; PubMed Central PMCID: PMCPMC3186336.
62. Flucke U, van Noesel MM, Siozopoulou V, Creytens D, Tops BBJ, van Gorp JM, et al.
EWSR1-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in
Different Bone Lesions: An Updated Review. Diagnostics (Basel). 2021;11(6). Epub 20210615.
doi: 10.3390/diagnostics11061093. PubMed PMID: 34203801; PubMed Central PMCID:
PMCPMC8232650.
63. Vlachos A, Osorio DS, Atsidaftos E, Kang J, Lababidi ML, Seiden HS, et al. The Increased
Prevalence of Congenital Heart Disease (CHD) in Children with Diamond Blackfan Anemia
(DBA) Suggests Unrecognized DBA as a Cause of CHD in the General Population: A Report of
the Diamond Blackfan Anemia Registry. Circ Genom Precis Med. 2018;11(5):e002044. doi:
10.1161/CIRCGENETICS.117.002044.
64. Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare
inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet.
2017;49(11):1593-601. doi: 10.1038/ng.3970.
65. Ye M, Coldren C, Liang X, Mattina T, Goldmuntz E, Benson DW, et al. Deletion of ETS-
1, a gene in the Jacobsen syndrome critical region, causes ventricular septal defects and abnormal
ventricular morphology in mice. Hum Mol Genet. 2010;19(4):648-56. Epub 20091126. doi:
10.1093/hmg/ddp532. PubMed PMID: 19942620; PubMed Central PMCID: PMCPMC2807373.
66. Kathiriya IS, Rao KS, Iacono G, Devine WP, Blair AP, Hota SK, et al. Modeling Human
TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease.
Developmental cell. 2021;56(3):292-309 e9. Epub 2020/12/16. doi:
10.1016/j.devcel.2020.11.020. PubMed PMID: 33321106; PubMed Central PMCID:
PMCPMC7878434.
67. Ang YS, Rivas RN, Ribeiro AJS, Srivas R, Rivera J, Stone NR, et al. Disease Model of
GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis. Cell.
2016;167(7):1734-49 e22. doi: 10.1016/j.cell.2016.11.033. PubMed PMID: 27984724; PubMed
Central PMCID: PMCPMC5180611.
68. Tanaka M, Yamaguchi S, Yamazaki Y, Kinoshita H, Kuwahara K, Nakao K, et al. Somatic
chromosomal translocation between Ewsr1 and Fli1 loci leads to dilated cardiomyopathy in a
mouse model. Sci Rep. 2015;5:7826. Epub 20150116. doi: 10.1038/srep07826. PubMed PMID:
25591392; PubMed Central PMCID: PMCPMC5379005.
69. Ragni CV, Diguet N, Le Garrec JF, Novotova M, Resende TP, Pop S, et al. Amotl1
mediates sequestration of the Hippo effector Yap1 downstream of Fat4 to restrict heart growth.
Nat Commun. 2017;8:14582. Epub 20170227. doi: 10.1038/ncomms14582. PubMed PMID:
28239148; PubMed Central PMCID: PMCPMC5333361.
70. Danilova N, Gazda HT. Ribosomopathies: how a common root can cause a tree of
pathologies. Dis Model Mech. 2015;8(9):1013-26. doi: 10.1242/dmm.020529.
71. Boulon S, Westman BJ, Hutten S, Boisvert F-M, Lamond AI. The nucleolus under stress.
Mol Cell. 2010;40(2):216-27. doi: 10.1016/j.molcel.2010.09.024.

72.   Yang K, Yang J, Yi J. Nucleolar Stress: hallmarks, sensing mechanism and diseases. Cell Stress. 2018;2(6):125-40. doi: 10.15698/cst2018.06.139.

73.   Dai M-S, Zeng SX, Jin Y, Sun X-X, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004;24(17):7654-68. doi: 10.1128/MCB.24.17.7654-7668.2004.

74.   Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5):369-77. doi: 10.1016/j.ccr.2009.09.024.

75.   Men H, Cai H, Cheng Q, Zhou W, Wang X, Huang S, et al. The regulatory roles of p53 in cardiovascular health and disease. Cell Mol Life Sci. 2021;78(5):2001-18. Epub 20201111. doi: 10.1007/s00018-020-03694-6. PubMed PMID: 33179140.

76.   Mak TW, Hauck L, Grothe D, Billia F. p53 regulates the cardiac transcriptome. Proc Natl Acad Sci U S A. 2017;114(9):2331-6. Epub 20170213. doi: 10.1073/pnas.1621436114. PubMed PMID: 28193895; PubMed Central PMCID: PMCPMC5338492.

77.   Deisenroth C, Zhang Y. The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism. Genes Cancer. 2011;2(4):392-403. doi: 10.1177/1947601911409737.

78.   Liu Y, Deisenroth C, Zhang Y. RP–MDM2–p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance. Trends Cancer. 2016;2(4):191-204. doi: 10.1016/j.trecan.2016.03.002.

79.   Cui Z, DiMario PJ. RNAi knockdown of Nopp140 induces Minute-like phenotypes in Drosophila. Mol Biol Cell. 2007;18(6):2179-91. doi: 10.1091/mbc.e07-01-0074.

80.   Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med. 2014;3:25. doi: 10.1186/2001-1326-3-25.

81.   Del Re DP. The hippo signaling pathway: implications for heart regeneration and disease. Clin Transl Med. 2014;3(1):27. doi: 10.1186/s40169-014-0027-0.

82.   Yu L, Daniels JP, Wu H, Wolf MJ. Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription. Sci Signal. 2015;8(362):ra13-ra. doi: 10.1126/scisignal.2005719.

83.   Wang J, Liu S, Heallen T, Martin JF. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat Rev Cardiol. 2018;15(11):672-84. doi: 10.1038/s41569-018-0063-3.

84.   Xiao Y, Leach J, Wang J, Martin JF. Hippo/Yap Signaling in Cardiac Development and Regeneration. Curr Treat Options Cardiovasc Med. 2016;18(6):38. doi: 10.1007/s11936-016-0461-y.

85.   von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(7):2394-9. doi: 10.1073/pnas.1116136109.

86.   Del Re DP, Yang Y, Nakano N, Cho J, Zhai P, Yamamoto T, et al. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J Biol Chem. 2013;288(6):3977-88. doi: 10.1074/jbc.M112.436311.

87.   Gifford CA, Ranade SS, Samarakoon R, Salunga HT, de Soysa TY, Huang Y, et al. Oligogenic inheritance of a human heart disease involving a genetic modifier. Science. 2019;364(6443):865-70. Epub 20190530. doi: 10.1126/science.aat5056. PubMed PMID: 31147515; PubMed Central PMCID: PMCPMC6557373.

88.   Birla AK, Brimmer S, Short WD, Olutoye OO, 2nd, Shar JA, Lalwani S, et al. Current state of the art in hypoplastic left heart syndrome. Front Cardiovasc Med. 2022;9:878266. Epub 20221028. doi: 10.3389/fcvm.2022.878266. PubMed PMID: 36386362; PubMed Central PMCID: PMCPMC9651920.

89.   Theis JL, Vogler G, Missinato MA, Li X, Nielsen T, Zeng XI, et al. Patient-specific
genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.
eLife. 2020;9. Epub 2020/10/03. doi: 10.7554/eLife.59554. PubMed PMID: 33006316; PubMed
Central PMCID: PMCPMC7581429.
90.   Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, et al. Intrinsic Endocardial Defects
Contribute to Hypoplastic Left Heart Syndrome. Cell stem cell. 2020;27(4):574-89 e8. Epub
20200817. doi: 10.1016/j.stem.2020.07.015. PubMed PMID: 32810435; PubMed Central PMCID:
PMCPMC7541479.
91.   Xu X, Jin K, Bais AS, Zhu W, Yagi H, Feinstein TN, et al. Uncompensated mitochondrial
oxidative stress underlies heart failure in an iPSC-derived model of congenital heart disease. Cell
stem cell. 2022;29(5):840-55 e7. Epub 20220407. doi: 10.1016/j.stem.2022.03.003. PubMed
PMID: 35395180; PubMed Central PMCID: PMCPMC9302582.
92.   Bray MA, Singh S, Han H, Davis CT, Borgeson B, Hartland C, et al. Cell Painting, a high-
content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nature
protocols. 2016;11(9):1757-74. Epub 20160825. doi: 10.1038/nprot.2016.105. PubMed PMID:
27560178; PubMed Central PMCID: PMCPMC5223290.
93.   Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7.
94.   Grodecká L, Kramárek M, Lockerová P, Kováčová T, Ravčuková B, Richterová R, et al.
No major effect of the CDH1 c.2440-6C>G mutation on splicing detected in last exon-specific
splicing minigene assay. Genes, Chromosomes and Cancer. 2014;53(9):798-801. doi:
https://doi.org/10.1002/gcc.22186.
95.   Burridge PW, Holmström A, Wu JC. Chemically Defined Culture and Cardiomyocyte
Differentiation of Human Pluripotent Stem Cells. Curr Protoc Hum Genet. 2015;87:21.3.1-.3.15.
doi: 10.1002/0471142905.hg2103s87.
96.   Pei F, Jiang J, Bai S, Cao H, Tian L, Zhao Y, et al. Chemical-defined and albumin-free
generation of human atrial and ventricular myocytes from human pluripotent stem cells. Stem Cell
Research. 2017;19:94-103. doi: 10.1016/j.scr.2017.01.006.
97.   Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core
framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276-8.
doi: 10.1038/s41587-020-0439-x. PubMed PMID: 32055031.
98.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.
PubMed PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.
99.   Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web
server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic
Acids Res. 2019;47(W1):W191-W8. doi: 10.1093/nar/gkz369. PubMed PMID: 31066453;
PubMed Central PMCID: PMCPMC6602461.
100.   Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, et al. An integrative
approach to ortholog prediction for disease-focused and other functional studies. BMC
Bioinformatics. 2011;12:357. doi: 10.1186/1471-2105-12-357. PubMed PMID: 21880147;
PubMed Central PMCID: PMCPMC3179972.
101.   Han Z, Yi P, Li X, Olson EN. Hand, an evolutionarily conserved bHLH transcription factor
required for Drosophila cardiogenesis and hematopoiesis. Development. 2006;133(6):1175-82.
doi: 10.1242/dev.02285.

102. Tögel M, Meyer H, Lehmacher C, Heinisch JJ, Pass G, Paululat A. The bHLH transcription
factor hand is required for proper wing heart formation in Drosophila. Dev Biol. 2013;381(2):446-
59. doi: 10.1016/j.ydbio.2013.05.027.
103. Hallier B, Hoffmann J, Roeder T, Tögel M, Meyer H, Paululat A. The bHLH Transcription
Factor Hand Regulates the Expression of Genes Critical to Heart and Muscle Function in
Drosophila melanogaster. PLOS ONE. 2015;10(8):e0134204. doi: 10.1371/journal.pone.0134204.
104. Vogler G. gvogler/FlyHearts-tdtK-Rscripts: First release of the R tdtK script. First ed:
Zenodo; 2021.
105. Cammarato A, Ocorr S, Ocorr K. Enhanced assessment of contractile dynamics in
Drosophila hearts. BioTechniques. 2015;58(2):77-80. doi: 10.2144/000114255. PubMed PMID:
25652030.
106. Alayari NN, Vogler G, Taghli-Lamallem O, Ocorr K, Bodmer R, Cammarato A.
Fluorescent labeling of Drosophila heart structures. J Vis Exp. 2009;(32). doi: 10.3791/1423.
107. Ocorr K, Vogler G, Bodmer R. Methods to assess Drosophila heart development, function
and aging. Methods. 2014;68(1):265-72. doi: 10.1016/j.ymeth.2014.03.031.
108. Huang C-J, Tu C-T, Hsiao C-D, Hsieh F-J, Tsai H-J. Germ-line transmission of a
myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin
light chain 2 promoter of zebrafish. Dev Dyn. 2003;228(1):30-40. doi: 10.1002/dvdy.10356.
109. Schumacher JA, Bloomekatz J, Garavito-Aguilar ZV, Yelon D. tal1 Regulates the
formation of intercellular junctions and the maintenance of identity in the endocardium. Dev Biol.
2013;383(2):214-26. doi: 10.1016/j.ydbio.2013.09.019.
110. Westerfield M. The zebrafish book: A guide for the laboratory use of zebrafish
(Brachydanio rerio). 1993 ed: M. W, editor: University of Oregon Press; 1993.
111. Talbot JC, Amacher SL. A streamlined CRISPR pipeline to reliably generate zebrafish
frameshifting alleles. Zebrafish. 2014;11(6):583-5. doi: 10.1089/zeb.2014.1047.
112. Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Ahkmetova L, et al. Efficient
mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of
single-guide RNAs. PLOS ONE. 2014;9(5):e98186. doi: 10.1371/journal.pone.0098186.
113. Irion U, Krauss J, Nüsslein-Volhard C. Precise and efficient genome editing in zebrafish
using the CRISPR/Cas9 system. Development. 2014;141(24):4827-30. doi: 10.1242/dev.115584.
114. Ocorr K, Fink M, Cammarato A, Bernstein SI, Bodmer R. Semi-automated Optical
Heartbeat Analysis of Small Hearts. Journal of Visualized Experiments : JoVE. 2009;(31). doi:
10.3791/1435.
115. Zeng X-XI, Yelon D. Cadm4 restricts the production of cardiac outflow tract progenitor
cells. Cell Reports. 2014;7(4):951-60. doi: 10.1016/j.celrep.2014.04.013.
116. Pradhan A, Zeng X-XI, Sidhwani P, Marques SR, George V, Targoff KL, et al. FGF
signaling enforces cardiac chamber identity in the developing ventricle. Development.
2017;144(7):1328-38. doi: 10.1242/dev.143719.
117. Alexander J, Stainier DY, Yelon D. Screening mosaic F1 females for mutations affecting
zebrafish heart induction and patterning. Dev Genet. 1998;22(3):288-99. doi: 10.1002/(SICI)1520-
6408(1998)22:3<288::AID-DVG10>3.0.CO;2-2.
118. Hoshijima K, Jurynec MJ, Klatt Shaw D, Jacobi AM, Behlke MA, Grunwald DJ. Highly
Efficient CRISPR-Cas9-Based Methods for Generating Deletion Mutations and F0 Embryos that
Lack Gene Function in Zebrafish. Developmental Cell. 2019;51(5):645-57.e4. doi:
10.1016/j.devcel.2019.10.004.
1401

Figure 1

A Day 25 hPSC-CMs
18,055 siRNAs tested → 48h → EdU addition → 24h → Day 28
Automated Image Analysis
EdU assay ACTN2 DAPI
High-throughput Fluorescence Microscopy

B RPL/RPS genes; all siRNAs; Relative hPSC-CM numbers (CM) vs Relative EdU+, ACTN2+ CMs (EdU); 153 hits; CDKN1A; TP53; MDM2; CHEK1; RPS14

C siControl; siCDKN1A; siTP53; siRPS14; ACTN2, EdU, DAPI

D

Enrichment of 153 top hits (Biological Process, BP)

Term	P value	Genes
nuclear-transcribed mRNA catabolic process	1.94e-43	41
protein targeting to ER	3.17e-56	41
establishment of protein localization to organelle	9.35e-30	43
Ribosome	1.78e-46	42
signal transduction by p53 class mediator	4.87e-02	8
positive regulation of vascular endothelial growth factor signaling pathway	3.20e-02	2
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	3.73e-02	3
regulation of signal transduction by p53 class mediator	6.05e-03	8
ribosomal small subunit assembly	2.09e-07	6
ribosomal large subunit assembly	2.03e-06	6
negative regulation of smoothened signaling pathway	4.71e-02	3

E Genes — GO (BP): RIBOSOME; NEGATIVE REGULATION OF SMOOTHENED SIGNALING; POSITIVE REGULATION OF VEGF SIGNALING; SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR; % EdU+ CM 0 to 0.5

Figure 2

A

HLHS trios with poor outcome (n = 25)

Variant Filter
MAF<1%, Missense, Loss of Function, Canonical Splice, Promotor

Gene Filter
Upper Quartile Fetal Heart Expression

Inheritance Filter
De novo (26)
Compound heterozygous (196)
X-linked recessive (83)
Homozygous recessive (12)

Enrichment analysis
(292 unique genes)
Protein class
Ribosomal protein (5.24-fold, p=0.0028)
Cellular component
Large Ribosomal Subunit (7.27-fold, p=0.011)

B

Labeled points: RPS28, RPS15, RPS17, RPL26L1, RPL39, RPL36A–HNRNPH2, RPL13A, RPL36A, RPL10, RPL3L

Y-axis: -log(P-Value)
X-axis: Normalized EdU+ CMs

C

control
heart-loss — RpL26 KD
heart-loss — RpL3 KD
normal — RpL13A KD
heart-loss — RpL36A KD
constriction — RpL10 KD
ostia — RpS28b KD

Hand [4.2]*-Gal4; R94C02::tdTom x RNAi*

D

control

rps17 CRISPR

rps28 CRISPR

rpl39 MO

72 hpf

E

Systolic Area Change (μm²)
Atrium — Control, rps17 CRISPR, rps28 CRISPR
Ventricle — Control, rps17 CRISPR, rps28 CRISPR

Diastolic SA (μm²)
Atrium — Control, rpl39 MO
Ventricle — Control, rpl39 MO

Figure 3

Figure 4

A siRPs vs siControl

hiPSC-CMs

RNAseq

siRPL39 512   745 (52.7%)   siRPS15A 157

CMs
differentially expressed genes
(vs. si-control, p.adj < 0.05)

B genes

GO terms (BP)

CDKN1A

DNA REPLICATION INITIATION

MITOTIC G1 DNA DAMAGE CHECKPOINT SIGNALING

DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN CELL CYCLE ARREST

RPL39 vs ctrl CMs
logFC
-2   2

C hPSC-CMs (28d)

Normalized % of ACTN2+, CDKN1A+ cells

siControl   siRPS15A

****

D hPSC-CMs (28d)

siControl

siRPS15A

ACTN2 CDKN1A

E

Normalized % of ACTN2+, EdU+ cells

siControl   siControl   siCDKN1A   siTP53

siRPS15A +

****   ****

F hPSC-CMs (28d)

siControl   siRPS15A

siRPS15A+CDKN1A   siRPS15A+TP53

ACTN2, EdU

G

Number of myl:eGFP; myl7:H2A-mCherry + cells

Control   rps15a MO   p53 MO   rps15a + p53 MO

****   ****   ****

H zebrafish

72 hpf

30 μm

V   A   control

V   A   rps15a MO

V   A   P53 MO

V   A   rps15a + P53 MO

myl:eGFP; myl7:H2A-mCherry

Figure 5

Figure 6

A

Normalized number of ACTN2+ cells

- siGATA6
- siNKX2−5
- siTBX5
- siGATA5
- siGATA4
- siHOPX
- siHES4

Normalized % of ACTN2, EDU + cells

B

siControl (0.5nM)   siRPS15A (0.5nM)   siRPL39 (0.5nM)

% of ACTN2, EDU + cells

siTBX5 dosage (nM)

siRPS15A:
dosage TBX5 p = 0.2
RP-knockdown p = 0.0013
RP:dosage interaction p = 0.004

siRPL39:
dosage TBX5 p = 0.37
RP-knockdown p = 0.052
RP:dosage interaction p = 0.047

C

control | $tin^{346/+}$ | $pnr^{Df/+}$ | $DocA^{Df/+}$

$RpS15Aa^{Df/+}$ | $RpS15Aa^{Df/+} + tin^{346/+}$ | $RpS15Aa^{Df/+} + pnr^{Df/+}$ | $RpS15Aa^{Df/+} + DocA^{Df/+}$

50 μm

D

heart phenotype
- severe
- minor
- normal

% (Flies)

n= 14 15 11 10 5 5 7 13 7 17

control, $RpS15Aa^{Df/+}$, $tin^{346/+}$, $RpS15Aa^{Df/+}; tin^{346/+}$, $pnr^{Df/+}$, $RpS15Aa^{Df/+}; pnr^{Df/+}$, $pnr^{VX6/+}$, $RpS15Aa^{Df/+}; pnr^{VX6/+}$, $DocA^{Df/+}$, $RpS15Aa^{Df/+}; DocA^{Df/+}$

* ** *** p=0.057

Figure 8

HLHS cohort

Variant filtering
& prioritization

↓

Model system gene
testing

Whole genome
siRNA screen
in hiPSC-CMs

proposed HLHS-causing mechanism

HLHS-associated genes

*Cardiac TF
(i.e TBX5)*

RPs

*Cardiac specific
regulation*

*KIF1C, PKMYT1,
MDC1, EWSR1*

CDKN1A

FAT4, EPHA4

Affect Cell
Cycle in CMs

*Non cardiac-specific
regulation*

CDKN1A, COL4A5

Hippo pathway